
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7802686/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Updated Nomogram Predicting Lymph Node Invasion in Patients with Prostate Cancer Undergoing Extended Pelvic Lymph Node Dissection: The Essential Importance of Percentage of Positive Cores. European Urology, 2012, 61, 480-487.	0.9	594
2	Distribution of metastatic sites in patients with prostate cancer: A populationâ€based analysis. Prostate, 2014, 74, 210-216.	1.2	352
3	Age-Adjusted Incidence, Mortality, and Survival Rates of Stage-Specific Renal Cell Carcinoma in North America: A Trend Analysis. European Urology, 2011, 59, 135-141.	0.9	259
4	Impact of Adjuvant Radiotherapy on Survival of Patients With Node-Positive Prostate Cancer. Journal of Clinical Oncology, 2014, 32, 3939-3947.	0.8	246
5	Incidence, survival and mortality rates of stage-specific bladder cancer in United States: A trend analysis. Cancer Epidemiology, 2013, 37, 219-225.	0.8	222
6	Pelvic/Retroperitoneal Salvage Lymph Node Dissection for Patients Treated With Radical Prostatectomy With Biochemical Recurrence and Nodal Recurrence Detected by [11C]Choline Positron Emission Tomography/Computed Tomography. European Urology, 2011, 60, 935-943.	0.9	209
7	Genomic Classifier Identifies Men With Adverse Pathology After Radical Prostatectomy Who Benefit From Adjuvant Radiation Therapy. Journal of Clinical Oncology, 2015, 33, 944-951.	0.8	196
8	More Extensive Pelvic Lymph Node Dissection Improves Survival in Patients with Node-positive Prostate Cancer. European Urology, 2015, 67, 212-219.	0.9	178
9	Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. Journal of Clinical Oncology, 2017, 35, 1991-1998.	0.8	176
10	Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. Journal of Clinical Oncology, 2018, 36, 581-590.	0.8	162
11	A Competing-Risks Analysis of Survival After Alternative Treatment Modalities for Prostate Cancer Patients: 1988–2006. European Urology, 2011, 59, 88-95.	0.9	159
12	A Pragmatic Randomized Controlled Trial Examining the Impact of the Retzius-sparing Approach on Early Urinary Continence Recovery After Robot-assisted Radical Prostatectomy. European Urology, 2017, 72, 677-685.	0.9	154
13	Are Infertile Men Less Healthy than Fertile Men? Results of a Prospective Case-Control Survey. European Urology, 2009, 56, 1025-1032.	0.9	141
14	Identifying Optimal Candidates for Local Treatment of the Primary Tumor Among Patients Diagnosed with Metastatic Prostate Cancer: A SEER-based Study. European Urology, 2015, 67, 3-6.	0.9	136
15	Chronic Kidney Disease After Nephrectomy in Patients with Small Renal Masses: A Retrospective Observational Analysis. European Urology, 2012, 62, 696-703.	0.9	129
16	The Impact of Local Treatment on Overall Survival in Patients with Metastatic Prostate Cancer on Diagnosis: A National Cancer Data Base Analysis. European Urology, 2017, 72, 14-19.	0.9	128
17	A Non–Cancer-Related Survival Benefit Is Associated With Partial Nephrectomy. European Urology, 2012, 61, 725-731.	0.9	124
18	Performance Characteristics of Computed Tomography in Detecting Lymph Node Metastases in Contemporary Patients with Prostate Cancer Treated with Extended Pelvic Lymph Node Dissection. European Urology, 2012, 61, 1132-1138.	0.9	120

#	Article	IF	CITATIONS
19	Identifying the Best Candidate for Radical Prostatectomy Among Patients with High-Risk Prostate Cancer. European Urology, 2012, 61, 584-592.	0.9	112
20	Functional Recovery, Oncologic Outcomes and Postoperative Complications after Robot-Assisted Radical Prostatectomy: An Evidence-Based Analysis Comparing the Retzius Sparing and Standard Approaches. Journal of Urology, 2018, 199, 1210-1217.	0.2	112
21	Management of Localized Kidney Cancer: Calculating Cancer-specific Mortality and Competing Risks of Death for Surgery and Nonsurgical Management. European Urology, 2014, 65, 235-241.	0.9	110
22	Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. European Urology, 2017, 72, 483-487.	0.9	110
23	Nerveâ€sparing approach during radical prostatectomy is strongly associated with the rate of postoperative urinary continence recovery. BJU International, 2013, 111, 717-722.	1.3	108
24	Selecting the Optimal Candidate for Adjuvant Radiotherapy After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. European Urology, 2013, 63, 998-1008.	0.9	107
25	Prostate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations. JAMA - Journal of the American Medical Association, 2015, 314, 2077.	3.8	105
26	Racial/Ethnic Disparities in Perioperative Outcomes of Major Procedures. Annals of Surgery, 2015, 262, 955-964.	2.1	101
27	Local Therapy Improves Survival in Metastatic Prostate Cancer. European Urology, 2017, 72, 118-124.	0.9	100
28	Impact of Age and Comorbidities on Long-term Survival of Patients with High-risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-institutional Competing-risks Analysis. European Urology, 2013, 63, 693-701.	0.9	98
29	Comparative Effectiveness of Robot-assisted Versus Open Radical Prostatectomy Cancer Control. European Urology, 2014, 66, 666-672.	0.9	97
30	Biopsy Schemes with the Fewest Cores for Detecting 95% of the Prostate Cancers Detected by a 24-Core Biopsy. European Urology, 2010, 57, 1-8.	0.9	94
31	Treatment Management of Small Renal Masses in the 21st Century: A Paradigm Shift. Annals of Surgical Oncology, 2012, 19, 2380-2387.	0.7	91
32	¹¹ C-Choline PET/CT Predicts Prostate Cancer–Specific Survival in Patients with Biochemical Failure During Androgen-Deprivation Therapy. Journal of Nuclear Medicine, 2014, 55, 233-241.	2.8	91
33	Contemporary Role of Salvage Lymphadenectomy in Patients with Recurrence Following Radical Prostatectomy. European Urology, 2015, 67, 839-849.	0.9	90
34	Impact of travel distance to the treatment facility on overall mortality in US patients with prostate cancer. Cancer, 2017, 123, 3241-3252.	2.0	89
35	Trans-rectal Versus Trans-Perineal Saturation Rebiopsy of the Prostate: Is There a Difference in Cancer Detection Rate?. Urology, 2011, 77, 921-925.	0.5	87
36	Head-to-Head Comparison of Prostate Health Index and Urinary PCA3 for Predicting Cancer at Initial or Repeat Biopsy. Journal of Urology, 2013, 190, 496-501.	0.2	87

#	Article	IF	CITATIONS
37	Extended pelvic lymph node dissection in prostate cancer: a 20-year audit in a single center. Annals of Oncology, 2013, 24, 1459-1466.	0.6	87
38	Predicting Survival of Patients with Node-positive Prostate Cancer Following Multimodal Treatment. European Urology, 2014, 65, 554-562.	0.9	86
39	Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. JAMA Oncology, 2016, 2, 85.	3.4	86
40	Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: A populationâ€based analysis. International Journal of Urology, 2012, 19, 836-844.	0.5	85
41	Decreasing Rate and Extent of Lymph Node Staging in Patients Undergoing Radical Prostatectomy May Undermine the Rate of Diagnosis of Lymph Node Metastases in Prostate Cancer. European Urology, 2010, 58, 882-892.	0.9	84
42	Long-term Cancer Control Outcomes in Patients with Clinically High-risk Prostate Cancer Treated with Robot-assisted Radical Prostatectomy: Results from a Multi-institutional Study of 1100 Patients. European Urology, 2015, 68, 497-505.	0.9	84
43	Impact of Adjuvant Radiation Therapy on Urinary Continence Recovery After Radical Prostatectomy. European Urology, 2014, 65, 546-551.	0.9	81
44	Lymphatic spread of nodal metastases in highâ€risk prostate cancer: The ascending pathway from the pelvis to the retroperitoneum. Prostate, 2012, 72, 186-192.	1.2	79
45	Contemporary incidence and mortality rates of kidney cancer in the United States. Canadian Urological Association Journal, 2014, 8, 247.	0.3	78
46	The impact of androgenâ€deprivation therapy (<scp>ADT</scp>) on the risk of cardiovascular (<scp>CV</scp>) events in patients with nonâ€metastatic prostate cancer: a populationâ€based study. BJU International, 2014, 114, E82-E89.	1.3	77
47	Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model. Journal of Clinical Oncology, 2017, 35, 1982-1990.	0.8	76
48	Prediction of Functional Outcomes After Nerve-Sparing Radical Prostatectomy: Results of Conditional Survival Analyses. European Urology, 2012, 62, 42-52.	0.9	75
49	Perioperative Mortality Is Significantly Greater in Septuagenarian and Octogenarian Patients Treated With Radical Cystectomy for Urothelial Carcinoma of the Bladder. Urology, 2011, 77, 660-666.	0.5	74
50	The Effect of Neoadjuvant Chemotherapy on Perioperative Outcomes in Patients Who Have Bladder Cancer Treated with Radical Cystectomy: A Population-based Study. European Urology, 2014, 66, 561-568.	0.9	70
51	Cancer-Specific and Other-Cause Mortality After Radical Prostatectomy Versus Observation in Patients with Prostate Cancer: Competing-Risks Analysis of a Large North American Population-Based Cohort. European Urology, 2011, 60, 920-930.	0.9	69
52	Racial disparities and socioeconomic status in men diagnosed with testicular germ cell tumors. Cancer, 2011, 117, 4277-4285.	2.0	69
53	Clinical Nodal Staging Scores for Bladder Cancer: A Proposal for Preoperative Risk Assessment. European Urology, 2012, 61, 237-242.	0.9	69
54	Extent of lymph node dissection at nephrectomy affects cancerâ€specific survival and metastatic progression in specific subâ€categories of patients with renal cell carcinoma (<scp>RCC</scp>). BJU International, 2014, 114, 210-215.	1.3	69

#	Article	IF	CITATIONS
55	The Effect of Body Mass Index on Perioperative Outcomes After Major Surgery: Results from the National Surgical Quality Improvement Program (ACSâ€NSQIP) 2005–2011. World Journal of Surgery, 2015, 39, 2376-2385.	0.8	69
56	Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy. European Urology, 2016, 70, 588-596.	0.9	69
57	Stage-specific impact of pelvic lymph node dissection on survival in patients with non-metastatic bladder cancer treated with radical cystectomy. BJU International, 2012, 109, 1147-1154.	1.3	64
58	Serum Sex Steroids Depict a Nonlinear U-Shaped Association with High-Risk Prostate Cancer at Radical Prostatectomy. Clinical Cancer Research, 2012, 18, 3648-3657.	3.2	62
59	Radical prostatectomy vs radiotherapy vs observation among older patients with clinically localized prostate cancer: a comparative effectiveness evaluation. BJU International, 2014, 113, 200-208.	1.3	61
60	Utility of [11C]choline PET/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: Results from a pathologically validated series. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 38.e9-38.e16.	0.8	61
61	Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA. European Urology Oncology, 2018, 1, 83-90.	2.6	59
62	How can we predict lymphorrhoea and clinically significant lymphocoeles after radical prostatectomy and pelvic lymphadenectomy? Clinical implications. BJU International, 2011, 107, 1095-1101.	1.3	58
63	Hospital Volume is a Determinant of Postoperative Complications, Blood Transfusion and Length of Stay After Radical or Partial Nephrectomy. Journal of Urology, 2012, 187, 405-410.	0.2	58
64	Predicting Life Expectancy in Men Diagnosed with Prostate Cancer. European Urology, 2015, 68, 756-765.	0.9	57
65	Mortality and Morbidity After Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Population-Based Study. Annals of Surgical Oncology, 2011, 18, 2988-2996.	0.7	55
66	Comparison of partial vs radical nephrectomy with regard to otherâ€cause mortality in T1 renal cell carcinoma among patients aged ≥75 years with multiple comorbidities. BJU International, 2013, 111, 67-73.	1.3	54
67	Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. European Urology, 2018, 74, 107-114.	0.9	54
68	Predicting the risk of bone metastasis in prostate cancer. Cancer Treatment Reviews, 2014, 40, 3-11.	3.4	53
69	Comparative effectiveness of robot-assisted vs. open radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 88.e1-88.e9.	0.8	52
70	The effect of marital status on stage and survival of prostate cancer patients treated with radical prostatectomy: a population-based study. Cancer Causes and Control, 2011, 22, 1085-1095.	0.8	51
71	In-hospital Mortality and Failure to Rescue After Cytoreductive Nephrectomy. European Urology, 2013, 63, 1107-1114.	0.9	51
72	Conditional survival of patients with urothelial carcinoma of the urinary bladder treated with radical cystectomy. European Journal of Cancer, 2012, 48, 1503-1511.	1.3	50

#	Article	IF	CITATIONS
73	Lymph node count threshold for optimal pelvic lymph node staging in prostate cancer. International Journal of Urology, 2012, 19, 645-651.	0.5	50
74	Impact of Adjuvant Radiotherapy in Node-positive Prostate Cancer Patients: The Importance of Patient Selection. European Urology, 2018, 74, 253-256.	0.9	48
75	Preoperative hypogonadism is not an independent predictor of highâ€risk disease in patients undergoing radical prostatectomy. Cancer, 2011, 117, 3953-3962.	2.0	47
76	The impact of resident involvement in minimally-invasive urologic oncology procedures. Canadian Urological Association Journal, 2014, 8, 334.	0.3	46
77	The impact of robot-assisted radical prostatectomy on the use and extent of pelvic lymph node dissection in the "post-dissemination―period. European Journal of Surgical Oncology, 2014, 40, 1080-1086.	0.5	46
78	Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis. European Urology, 2018, 73, 452-461.	0.9	46
79	Holmium laser enucleation of the prostate and holmium laser ablation of the prostate: indications and outcome. Current Opinion in Urology, 2009, 19, 38-43.	0.9	45
80	Metabolic Syndrome and Benign Prostatic Hyperplasia: Evidence of a Potential Relationship, Hypothesized Etiology, and Prevention. Korean Journal of Urology, 2011, 52, 507.	1.2	44
81	Survival after radical cystectomy of nonâ€bilharzial squamous cell carcinoma vs urothelial carcinoma: a competingâ€risks analysis. BJU International, 2012, 109, 564-569.	1.3	44
82	A Stage-for-Stage and Grade-for-Grade Analysis of Cancer-Specific Mortality Rates in Renal Cell Carcinoma According to Age: A Competing-Risks Regression Analysis. European Urology, 2011, 60, 1152-1159.	0.9	43
83	Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer. European Urology, 2015, 68, 32-39.	0.9	43
84	Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics. European Urology, 2018, 73, 445-451.	0.9	43
85	Contemporary Trends in the Incidence of Metastatic Prostate Cancer Among US Men: Results from Nationwide Analyses. European Urology Focus, 2019, 5, 77-80.	1.6	43
86	When to perform lymph node dissection in patients with renal cell carcinoma: a novel approach to the preoperative assessment of risk of lymph node invasion at surgery and of lymph node progression during followâ€up. BJU International, 2013, 112, E59-66.	1.3	42
87	Determinants of long-term survival of patients with locally advanced prostate cancer: the role of extensive pelvic lymph node dissection. Prostate Cancer and Prostatic Diseases, 2016, 19, 63-67.	2.0	41
88	Survival Benefit of Radical Prostatectomy in Patients with Localized Prostate Cancer: Estimations of the Number Needed to Treat According to Tumor and Patient Characteristics. Journal of Urology, 2012, 188, 73-83.	0.2	40
89	Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma. European Urology, 2017, 71, 714-718.	0.9	40
90	Variation in the use of active surveillance for lowâ€risk prostate cancer. Cancer, 2018, 124, 55-64.	2.0	40

#	Article	IF	CITATIONS
91	Survival Following Biochemical Recurrence After Radical Prostatectomy and Adjuvant Radiotherapy in Patients With Prostate Cancer: The Impact of Competing Causes of Mortality and Patient Stratification. European Urology, 2013, 64, 557-564.	0.9	39
92	Is Robot-Assisted Radical Prostatectomy Safe in Men with High-Risk Prostate Cancer? Assessment of Perioperative Outcomes, Positive Surgical Margins, and Use of Additional Cancer Treatments. Journal of Endourology, 2014, 28, 784-791.	1.1	39
93	Suicide and accidental deaths among patients with nonâ€metastatic prostate cancer. BJU International, 2016, 118, 286-297.	1.3	39
94	Does diabetes mellitus increase the risk of high-grade prostate cancer in patients undergoing radical prostatectomy?. Prostate Cancer and Prostatic Diseases, 2011, 14, 74-78.	2.0	38
95	A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer. European Urology Oncology, 2019, 2, 294-301.	2.6	38
96	Extent of lymphadenectomy does not improve the survival of patients with renal cell carcinoma and nodal metastases: biases associated with the handling of missing data. BJU International, 2014, 113, 36-42.	1.3	37
97	Racial Disparities in End-of-Life Care Among Patients With Prostate Cancer: A Population-Based Study. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1131-1138.	2.3	37
98	Racial disparity in quality of care and overall survival among black vs. white patients with muscle-invasive bladder cancer treated with radical cystectomy: A national cancer database analysis. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 469.e1-469.e11.	0.8	37
99	Development and Validation of a Reference Table for Prediction of Postoperative Mortality Rate in Patients Treated with Radical Cystectomy: A Population-based Study. Annals of Surgical Oncology, 2012, 19, 309-317.	0.7	36
100	Annual Surgical Caseload and Open Radical Prostatectomy Outcomes: Improving Temporal Trends. Journal of Urology, 2010, 184, 2285-2290.	0.2	35
101	Circulating estradiol, but not testosterone, is a significant predictor of highâ€grade prostate cancer in patients undergoing radical prostatectomy. Cancer, 2011, 117, 5029-5038.	2.0	35
102	Preoperative Erectile Function Represents a Significant Predictor of Postoperative Urinary Continence Recovery in Patients Treated With Bilateral Nerve Sparing Radical Prostatectomy. Journal of Urology, 2012, 187, 569-574.	0.2	35
103	Choosing the Best Candidates for Penile Rehabilitation After Bilateral Nerve-Sparing Radical Prostatectomy. Journal of Sexual Medicine, 2012, 9, 608-617.	0.3	35
104	Rates of open versus laparoscopic and partial versus radical nephrectomy for <scp>T</scp> 1a renal cell carcinoma: A populationâ€based evaluation. International Journal of Urology, 2013, 20, 1064-1071.	0.5	35
105	A Contemporary Population-Based Assessment of the Rate of Lymph Node Dissection for Penile Carcinoma. Annals of Surgical Oncology, 2011, 18, 439-446.	0.7	34
106	Conditional survival predictions after surgery for patients with penile carcinoma. Cancer, 2011, 117, 3723-3730.	2.0	34
107	Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasoundâ€guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy. BJU International, 2012, 110, E64-8.	1.3	34
108	Conditional survival after nephrectomy for renal cell carcinoma (<scp>RCC</scp>): changes in future survival probability over time. BJU International, 2013, 111, E283-9.	1.3	33

#	Article	IF	CITATIONS
109	A population-based analysis of the effect of marital status on overall and cancer-specific mortality in patients with squamous cell carcinoma of the penis. Cancer Causes and Control, 2013, 24, 71-79.	0.8	33
110	Impact of the introduction of a robotic training programme on prostate cancer stage migration at a single tertiary referral centre. BJU International, 2013, 111, 1222-1230.	1.3	33
111	External Validation of the European Association of Urology Recommendations for Pelvic Lymph Node Dissection in Patients Treated with Robot-Assisted Radical Prostatectomy. Journal of Endourology, 2014, 28, 416-423.	1.1	33
112	Differential effect on survival of pelvic lymph node dissection at radical cystectomy for muscle invasive bladder cancer. European Journal of Surgical Oncology, 2015, 41, 353-360.	0.5	33
113	Decipher correlation patterns post prostatectomy: initial experience from 2 342 prospective patients. Prostate Cancer and Prostatic Diseases, 2016, 19, 374-379.	2.0	33
114	Validation of a Genomic Classifier for Predicting Post-Prostatectomy Recurrence in a Community Based Health Care Setting. Journal of Urology, 2016, 195, 1748-1753.	0.2	33
115	The Association between Mortality and Distance to Treatment Facility in Patients with Muscle Invasive Bladder Cancer. Journal of Urology, 2018, 199, 424-429.	0.2	33
116	The Optimal Rebiopsy Prostatic Scheme Depends on Patient Clinical Characteristics: Results of a Recursive Partitioning Analysis Based on a 24-Core Systematic Scheme. European Urology, 2011, 60, 834-841.	0.9	32
117	Propensity-score matched comparison of complications, blood transfusions, length of stay, and in-hospital mortality between open and laparoscopic partial nephrectomy: A national series. European Journal of Surgical Oncology, 2012, 38, 80-87.	0.5	32
118	Determinants of Prostate Specific Antigen Screening among Black Men in the United States in the Contemporary Era. Journal of Urology, 2016, 195, 913-918.	0.2	32
119	First North American validation and headâ€ŧoâ€head comparison of four preoperative nomograms for prediction of lymph node invasion before radical prostatectomy. BJU International, 2018, 121, 592-599.	1.3	32
120	Cytoreductive Nephrectomy: Assessing the Generalizability of the CARMENA Trial to Real-world National Cancer Data Base Cases. European Urology, 2019, 75, 352-353.	0.9	32
121	The role of transrectal saturation biopsy in tumour localization: pathological correlation after retropubic radical prostatectomy and implication for focal ablative therapy. BJU International, 2011, 108, 366-371.	1.3	31
122	Erectile Function Outcome after Bilateral Nerve Sparing Radical Prostatectomy: Which Patients May Be Left Untreated?. Journal of Sexual Medicine, 2012, 9, 903-908.	0.3	31
123	Is a Treatment Delay in Radical Prostatectomy Safe in Individuals with Lowâ€Risk Prostate Cancer?. Journal of Sexual Medicine, 2012, 9, 2961-2969.	0.3	31
124	Preoperative sex steroids are significant predictors of early biochemical recurrence after radical prostatectomy. World Journal of Urology, 2013, 31, 275-280.	1.2	31
125	Tumor Grade Improves the Prognostic Ability of American Joint Committee on Cancer Stage in Patients With Penile Carcinoma. Journal of Urology, 2011, 185, 501-507.	0.2	29
126	Indications for Pelvic Nodal Treatment in Prostate Cancer Should Change. Validation of the Roach Formula in a Large Extended Nodal Dissection Series. International Journal of Radiation Oncology Biology Physics, 2012, 83, 624-629.	0.4	29

#	Article	IF	CITATIONS
127	Cytoreductive nephrectomy in the elderly: a populationâ€based cohort from the USA. BJU International, 2012, 109, 1807-1812.	1.3	29
128	Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer. European Urology, 2014, 66, 1125-1132.	0.9	29
129	Competing-Risks Mortality After Radiotherapy vs. Observation for Localized Prostate Cancer: A Population-based Study. International Journal of Radiation Oncology Biology Physics, 2012, 84, 95-103.	0.4	28
130	Head-to-head comparison of lymph node density and number of positive lymph nodes in stratifying the outcome of patients with lymph node-positive prostate cancer submitted to radical prostatectomy and extended lymph node dissection. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 29.e21-29.e28.	0.8	28
131	The influence of physician recommendation on prostate-specific antigen screening. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 424.e1-424.e7.	0.8	28
132	Prostate Cancer Screening in Early Medicaid Expansion States. Journal of Urology, 2018, 199, 81-88.	0.2	28
133	External Validation of the Updated Nomogram Predicting Lymph Node Invasion in Patients with Prostate Cancer Undergoing Extended Pelvic Lymph Node Dissection. Urologia Internationalis, 2013, 90, 277-282.	0.6	27
134	An Evaluation of the Timing of Surgical Complications Following Radical Cystectomy: Data From the American College of Surgeons National Surgical Quality Improvement Program. Urology, 2017, 103, 91-98.	0.5	27
135	Risk Factors for Intravesical Recurrence after Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Cancer (ROBUUST Collaboration). Journal of Urology, 2021, 206, 568-576.	0.2	27
136	The Extent of Lymphadenectomy does Affect Cancer Specific Survival in Pathologically Confirmed T4 Renal Cell Carcinoma. Urologia, 2012, 79, 109-115.	0.3	26
137	Influence of obesity on tumour volume in patients with prostate cancer. BJU International, 2012, 109, 678-684.	1.3	26
138	An evaluation of the timing of surgical complications following nephrectomy: data from the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP). World Journal of Urology, 2015, 33, 2031-2038.	1.2	26
139	COVID-19 Infection in Men on Testosterone Replacement Therapy. Journal of Sexual Medicine, 2021, 18, 215-218.	0.3	26
140	Application of Ice Cold Irrigation During Vascular Pedicle Control of Robot-Assisted Radical Prostatectomy: EnSeal Instrument Cooling to Reduce Collateral Thermal Tissue Damage. Journal of Endourology, 2010, 24, 1991-1996.	1.1	25
141	Prostate Saturation Biopsy following a First Negative Biopsy: State of the Art. Urologia Internationalis, 2012, 89, 126-135.	0.6	25
142	A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 46.e1-46.e7.	0.8	25
143	Impact of Caseload on Total Hospital Charges: A Direct Comparison Between Minimally Invasive and Open Radical Prostatectomy—A Population Based Study. Journal of Urology, 2011, 185, 855-861.	0.2	24
144	Clinical nodal staging scores for prostate cancer: a proposal for preoperative risk assessment. British Journal of Cancer, 2014, 111, 213-219.	2.9	24

#	Article	IF	CITATIONS
145	Pathologic Nodal Staging Scores in Patients Treated with Radical Prostatectomy: A Postoperative Decision Tool. European Urology, 2014, 66, 439-446.	0.9	24
146	Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy. Clinical Cancer Research, 2018, 24, 3908-3916.	3.2	24
147	Contemporary Role of the Decipher® Test in Prostate Cancer Management: Current Practice and Future Perspectives. Reviews in Urology, 2016, 18, 1-9.	0.9	24
148	National Comprehensive Cancer Network Practice Guidelines 2011: Need for More Accurate Recommendations for Pelvic Lymph Node Dissection in Prostate Cancer. Journal of Urology, 2012, 188, 423-428.	0.2	23
149	A Comparison of 30-Day Perioperative Outcomes in Open Versus Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Carcinoma: Analysis of 896 Patients from the American College of Surgeons-National Surgical Quality Improvement Program Database. Journal of Endourology. 2015. 29. 1052-1058.	1.1	23
150	Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk. Prostate Cancer and Prostatic Diseases, 2016, 19, 277-282.	2.0	23
151	Robotic Kidney Transplantation with Regional Hypothermia versus Open Kidney Transplantation for Patients with End Stage Renal Disease: An Ideal Stage 2B Study. Journal of Urology, 2021, 205, 595-602.	0.2	23
152	Nodal involvement at nephrectomy is associated with worse survival: A stage-for-stage and grade-for-grade analysis. International Journal of Urology, 2013, 20, 372-380.	0.5	22
153	Effect of number and location of distant metastases on renal cell carcinoma mortality in candidates for cytoreductive nephrectomy: Implications for multimodal therapy. International Journal of Urology, 2013, 20, 572-579.	0.5	22
154	Benefit in regionalisation of care for patients treated with radical cystectomy: a nationwide inpatient sample analysis. BJU International, 2014, 113, 733-740.	1.3	22
155	Percentage of highâ€grade tumour volume does not meaningfully improve prediction of early biochemical recurrence after radical prostatectomy compared with <scp>G</scp> leason score. BJU International, 2014, 113, 399-407.	1.3	22
156	Long-term survival in patients with germ cell testicular cancer: A population-based competing-risks regression analysis. European Journal of Surgical Oncology, 2014, 40, 103-112.	0.5	22
157	Early radiotherapy after radical prostatectomy improves cancerâ€specific survival only in patients with highly aggressive prostate cancer: Validation of recently released criteria. International Journal of Urology, 2015, 22, 89-95.	0.5	22
158	Doseâ€dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events. BJU International, 2016, 118, 221-229.	1.3	22
159	Racial differences in prostate-specific antigen–based prostate cancer screening: State-by-state and region-by-region analyses. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 460.e20.	0.8	22
160	Generalizability of the Prostate Cancer Intervention Versus Observation Trial (PIVOT) Results to Contemporary North American Men with Prostate Cancer. European Urology, 2017, 71, 511-514.	0.9	22
161	Rare Histological Variants of Prostate Adenocarcinoma: A National Cancer Database Analysis. Journal of Urology, 2020, 204, 260-266.	0.2	22
162	Robotic <i>vs</i> Laparoscopic Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multicenter Propensity-Score Matched Pair "tetrafecta―Analysis (ROBUUST Collaborative Group). Journal of Endourology, 2022, 36, 752-759.	1.1	22

#	Article	IF	CITATIONS
163	Impact of Surgical Experience on In-Hospital Complication Rates in Patients Undergoing Minimally Invasive Prostatectomy: A Population-Based Study. Annals of Surgical Oncology, 2011, 18, 839-847.	0.7	21
164	A critical assessment of the value of lymph node dissection at radical prostatectomy: A populationâ€based study. Prostate, 2011, 71, 1587-1594.	1.2	21
165	Pelvic lymph node dissection for prostate cancer: Adherence and accuracy of the recent guidelines. International Journal of Urology, 2013, 20, 405-410.	0.5	21
166	Postoperative phosphodiesterase type 5 inhibitor administration increases the rate of urinary continence recovery after bilateral nerveâ€sparing radical prostatectomy. International Journal of Urology, 2013, 20, 413-419.	0.5	21
167	Populationâ€Based External Validation of the Updated 2012 Partin Tables in Contemporary North American Prostate Cancer Patients. Prostate, 2017, 77, 105-113.	1.2	21
168	Comparison of Partial Versus Radical Nephrectomy Effect on Other-cause Mortality, Cancer-specific Mortality, and 30-day Mortality in Patients Older Than 75 Years. European Urology Focus, 2019, 5, 467-473.	1.6	21
169	Critical assessment of the European Association of Urology guideline indications for pelvic lymph node dissection at radical prostatectomy. BJU International, 2011, 108, 1769-1775.	1.3	20
170	A Population-Based Analysis of Temporal Perioperative Complication Rates After Minimally Invasive Radical Prostatectomy. European Urology, 2011, 60, 564-571.	0.9	20
171	Survival after nephroureterectomy for upper tract urothelial carcinoma: A populationâ€based competingâ€risks analysis. International Journal of Urology, 2014, 21, 249-256.	0.5	20
172	Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: estimations of the number needed to treat based on competingâ€risks analysis. BJU International, 2014, 114, E62-E69.	1.3	20
173	Staging lymphadenectomy in renal cell carcinoma must be extended: a sensitivity curve analysis. BJU International, 2013, 111, 412-418.	1.3	19
174	The Number of Cores Taken in Patients Diagnosed with a Single Microfocus at Initial Biopsy is a Major Predictor of Insignificant Prostate Cancer. Journal of Urology, 2013, 189, 854-859.	0.2	19
175	Tumor volume improves the long-term prediction of biochemical recurrence-free survival after radical prostatectomy for localized prostate cancer with positive surgical margins. World Journal of Urology, 2017, 35, 199-206.	1.2	19
176	The Impact of Lymph Node Metastases Burden at Radical Prostatectomy. European Urology Focus, 2019, 5, 399-406.	1.6	19
177	Does Educational Status Affect a Patient's Behavior Toward Erectile Dysfunction?. Journal of Sexual Medicine, 2008, 5, 1941-1948.	0.3	18
178	Blood Transfusions in Radical Prostatectomy: A Contemporary Population-based Analysis. Urology, 2012, 79, 332-338.	0.5	18
179	Diagnosis of isolated highâ€grade prostatic intraâ€epithelial neoplasia: proposal of a nomogram for the prediction of cancer detection at saturation reâ€biopsy. BJU International, 2012, 109, 1329-1334.	1.3	18
180	Assessing the most accurate formula to predict the risk of lymph node metastases from prostate cancer in contemporary patients treated with radical prostatectomy and extended pelvic lymph node dissection. Radiotherapy and Oncology, 2013, 109, 211-216.	0.3	18

#	Article	IF	CITATIONS
181	Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥66 years. European Journal of Surgical Oncology, 2015, 41, 1529-1539.	0.5	18
182	Therapeutic Value of Standard Versus Extended Pelvic Lymph Node Dissection During Radical Prostatectomy for High-Risk Prostate Cancer. Current Urology Reports, 2017, 18, 51.	1.0	18
183	Long-term Risk of Recurrence in Surgically Treated Renal Cell Carcinoma: A Post Hoc Analysis of the Eastern Cooperative Oncology Group—American College of Radiology Imaging Network E2805 Trial Cohort. European Urology, 2020, 77, 277-281.	0.9	18
184	Extended Pelvic Lymph Node Dissection Does Not Affect Erectile Function Recovery in Patients Treated with Bilateral Nerveâ€Sparing Radical Prostatectomy. Journal of Sexual Medicine, 2012, 9, 2187-2194.	0.3	17
185	Treatment of Lymph Node–Positive Prostate Cancer: Teaching Old Dogmas New Tricks. European Urology, 2014, 65, 26-28.	0.9	17
186	The Impact of Insurance Status on Tumor Characteristics and Treatment Selection in Contemporary Patients With Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1351-1358.	2.3	17
187	Variation in Locoregional Prostate Cancer Care and Treatment Trends at Commission on Cancer Designated Facilities: A National Cancer Data Base Analysis 2004 to 2013. Clinical Genitourinary Cancer, 2017, 15, e955-e968.	0.9	17
188	Head-to-head Comparison of Three Commonly Used Preoperative Tools for Prediction of Lymph Node Invasion at Radical Prostatectomy. Urology, 2011, 78, 1363-1367.	0.5	16
189	The Importance of Pelvic Lymph Node Dissection in the Elderly Population: Implications for Interpreting the 2010 National Comprehensive Cancer Network Practice Guidelines for Bladder Cancer Treatment. Journal of Urology, 2011, 185, 2078-2084.	0.2	16
190	Are Caucasian–European men delaying fatherhood? Results of a 7 year observational study of infertile couples with male factor infertility. Journal of Developmental and Physical Disabilities, 2012, 35, 125-132.	3.6	16
191	Pelvic Lymph Node Dissection in Prostate Cancer: The Mystery Is Taking Shape. European Urology, 2013, 63, 459-461.	0.9	16
192	A novel tool to assess the risk of urinary incontinence after nerveâ€sparing radical prostatectomy. BJU International, 2013, 111, 905-913.	1.3	16
193	Effect of Preoperative Angina Pectoris on Cardiac Outcomes in Patients With Previous Myocardial Infarction Undergoing Major Noncardiac Surgery (Data from ACS-NSQIP). American Journal of Cardiology, 2015, 115, 1080-1084.	0.7	16
194	Comparison of 30-day perioperative outcomes in adults undergoing open versus minimally invasive pyeloplasty for ureteropelvic junction obstruction: analysis of 593 patients in a prospective national database. World Journal of Urology, 2015, 33, 2107-2113.	1.2	16
195	Evaluation of a genomic classifier in radical prostatectomy patients with lymph node metastasis. Research and Reports in Urology, 2016, Volume 8, 77-84.	0.6	16
196	10-Year Outcomes in Localized Prostate Cancer. New England Journal of Medicine, 2017, 376, 178-181.	13.9	16
197	Contemporary rates of pathological features and mortality for adenocarcinoma of the urinary bladder in the USA. International Journal of Urology, 2017, 24, 117-123.	0.5	16
198	Minimally Invasive or Abdominal Radical Hysterectomy for Cervical Cancer. New England Journal of Medicine, 2019, 380, 793-795.	13.9	16

#	Article	IF	CITATIONS
199	Nephroureterectomy with or without Bladder Cuff Excision for Localized Urothelial Carcinoma of the Renal Pelvis. European Urology Focus, 2020, 6, 298-304.	1.6	16
200	Single-stage Xi® robotic radical nephroureterectomy for upper tract urothelial carcinoma: surgical technique and outcomes. Minerva Urology and Nephrology, 2022, 74, .	1.3	16
201	Is Sperm Banking of Interest to Patients With Nongerm Cell Urological Cancer Before Potentially Fertility Damaging Treatments?. Journal of Urology, 2009, 182, 1101-1107.	0.2	15
202	Venous thromboembolism after radical prostatectomy: the effect of surgical caseload. BJU International, 2012, 110, 828-833.	1.3	15
203	An evidence-based guide to the selection of sequential therapies in metastatic renal cell carcinoma. Therapeutic Advances in Urology, 2013, 5, 121-128.	0.9	15
204	The effect of age at diagnosis on prostate cancer mortality: A grade-for-grade and stage-for-stage analysis. European Journal of Surgical Oncology, 2014, 40, 1706-1715.	0.5	15
205	North American Populationâ€Based Validation of the National Comprehensive Cancer Network Practice Guideline Recommendation of Pelvic Lymphadenectomy in Contemporary Prostate Cancer. Prostate, 2017, 77, 542-548.	1.2	15
206	Postoperative sepsis prediction in patients undergoing major cancer surgery. Journal of Surgical Research, 2017, 209, 60-69.	0.8	15
207	Contemporary Management of Prostate Cancer Patients Suitable for Active Surveillance: A North American Population-based Study. European Urology Focus, 2018, 4, 68-74.	1.6	15
208	Trends of Retroperitoneal Lymphadenectomy Use in Patients with Nonseminomatous Germ Cell Tumor of the Testis: A Population-Based Study. Annals of Surgical Oncology, 2011, 18, 2997-3004.	0.7	14
209	Assessing the risk of lymph node invasion in patients with intermediate risk prostate cancer treated with extended pelvic lymph node dissection. A novel prediction tool. Prostate, 2012, 72, 499-506.	1.2	14
210	Rate and Extent of Pelvic Lymph Node Dissection in the US Prostate Cancer Patients Treated With Radical Prostatectomy. Clinical Genitourinary Cancer, 2018, 16, e451-e467.	0.9	14
211	Presence of positive surgical margin in patients with organ-confined prostate cancer equals to extracapsular extension negative surgical margin. A plea for TNM staging system reclassification. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1497-1503.	0.8	13
212	Minimally invasive renal autotransplantation. Journal of Surgical Oncology, 2015, 112, 717-722.	0.8	13
213	Intermediate-term cancer control outcomes in prostate cancer patients treated with robotic-assisted laparoscopic radical prostatectomy: a multi-institutional analysis. World Journal of Urology, 2016, 34, 1357-1366.	1.2	13
214	Adverse Event Rates, Timing of Complications, and the Impact of Specialty on Outcomes Following Adrenal Surgery: An Analysis of 30-Day Outcome Data From the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP). Urology, 2016, 90, 62-68.	0.5	13
215	A contemporary analysis of radiotherapy effect in surgically treated retroperitoneal sarcoma. Radiotherapy and Oncology, 2018, 127, 318-325.	0.3	13
216	Outcomes of Lymph Node Dissection in Nephroureterectomy in the Treatment of Upper Tract Urothelial Carcinoma: Analysis of the ROBUUST Registry. Journal of Urology, 2022, , 101097JU000000000002690.	0.2	13

#	Article	IF	CITATIONS
217	Optimizing postoperative sexual function after radical prostatectomy. Therapeutic Advances in Urology, 2012, 4, 347-365.	0.9	12
218	Annual Prostatectomy Volume Is Related to Rectal Laceration Rate After Radical Prostatectomy. Urology, 2012, 79, 796-803.	0.5	12
219	There is no way to identify patients who will harbor small volume, unilateral prostate cancer at final pathology. Implications for focal therapies. Prostate, 2012, 72, 925-930.	1.2	12
220	Robotâ€assisted hepatic mobilization and control of suprahepatic infradiaphragmatic inferior vena cava for level 3 vena caval thrombectomy: An IDEAL stage 0 study. Journal of Surgical Oncology, 2015, 112, 741-745.	0.8	12
221	When Should a Positive Surgical Margin Ring a Bell? An Analysis of a Multi-Institutional Robot-Assisted Laparoscopic Radical Prostatectomy Database. Journal of Endourology, 2016, 30, 201-207.	1.1	12
222	Calculating life expectancy to inform prostate cancer screening and treatment decisions. BJU International, 2017, 120, 9-11.	1.3	12
223	Endocrine, Sexual Function, and Infertility Side Effects of Immune Checkpoint Inhibitor Therapy for Genitourinary Cancers. Current Urology Reports, 2018, 19, 68.	1.0	12
224	Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients. European Urology Focus, 2019, 5, 381-388.	1.6	12
225	Surgical Caseload is an Important Determinant of Continent Urinary Diversion Rate at Radical Cystectomy: A Population-Based Study. Annals of Surgical Oncology, 2011, 18, 2680-2687.	0.7	11
226	A populationâ€based assessment of the National Comprehensive Cancer Network practice guideline indications for pelvic lymph node dissection at radical prostatectomy. BJU International, 2012, 109, 1177-1182.	1.3	11
227	The key role of time in predicting progression-free survival in patients with renal cell carcinoma treated with partial or radical nephrectomy: Conditional survival analysis. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 43.e9-43.e16.	0.8	11
228	Predicting pathological outcomes in patients undergoing robot-assisted radical prostatectomy for high-risk prostate cancer: a preoperative nomogram. BJU International, 2015, 116, 703-712.	1.3	11
229	Preventable mortality after common urological surgery: failing to rescue?. BJU International, 2015, 115, 666-674.	1.3	11
230	Rates of Kidney Transplantation From Living and Deceased Donors for Blacks and Whites in the United States, 1998 to 2011. JAMA Internal Medicine, 2015, 175, 1716.	2.6	11
231	Understanding the Use of Prostate Biopsy Among Men with Limited Life Expectancy in a Statewide Quality Improvement Collaborative. European Urology, 2016, 70, 854-861.	0.9	11
232	Could lead-time bias explain the apparent benefits of early salvage radiotherapy?. Nature Reviews Urology, 2017, 14, 193-194.	1.9	11
233	Variation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer. Clinical Genitourinary Cancer, 2019, 17, e1060-e1068.	0.9	11
234	Role of robot-assisted radical prostatectomy in the management of high-risk prostate cancer. Indian Journal of Urology, 2014, 30, 410.	0.2	11

#	Article	IF	CITATIONS
235	Description of Surgical Technique and Oncologic and Functional Outcomes of the Precision Prostatectomy Procedure (IDEAL Stage 1–2b Study). European Urology, 2022, 81, 396-406.	0.9	11
236	Preoperative erectile function is the only predictor of the use of a high number of phosphodiesterase type-5 inhibitors after bilateral nerve-sparing radical prostatectomy. International Journal of Impotence Research, 2014, 26, 201-204.	1.0	10
237	Increasing Rate of Noninterventional Treatment Management in Localized Prostate Cancer Candidates for Active Surveillance: A North American Population-Based Study. Clinical Genitourinary Cancer, 2019, 17, 72-78.e4.	0.9	10
238	Ten-year disease progression and mortality rates in men who experience biochemical recurrence versus persistence after radical prostatectomy and undergo salvage radiation therapy: A post-hoc analysis of RTOG 9601 trial data. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 599.e1-599.e8.	0.8	10
239	Improving the stratification of intermediate risk prostate cancer. Minerva Urology and Nephrology, 2022, 74, .	1.3	10
240	Evaluating post radical prostatectomy mechanisms of early continence. Prostate, 2022, 82, 1186-1195.	1.2	10
241	Obesity does not increase the risk of lymph node metastases in patients with clinically localized prostate cancer undergoing radical prostatectomy and extended pelvic lymph node dissection. International Journal of Urology, 2009, 16, 676-681.	0.5	9
242	Hospital and Surgical Caseload are Predictors of Comprehensive Surgical Treatment for Bladder Cancer: A Population Based Study. Journal of Urology, 2011, 186, 824-828.	0.2	9
243	The impact of surgical experience on total hospital charges for minimally invasive prostatectomy: a populationâ€based study. BJU International, 2011, 108, 888-893.	1.3	9
244	Contemporary nationwide patterns of self-reported prostate-specific antigen screening in US veterans. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 503.e7-503.e15.	0.8	9
245	Robot-assisted partial cystectomy with intraoperative frozen section examination: Evolution and evaluation of a novel technique. Investigative and Clinical Urology, 2016, 57, 221.	1.0	9
246	Testing the external validity of the EORTC randomized trial 30904 comparing overall survival after radical nephrectomy vs nephronâ€sparing surgery in contemporary North American patients with renal cell cancer. BJU International, 2018, 121, 345-347.	1.3	9
247	Omission of Cortical Renorrhaphy During Robotic Partial Nephrectomy: A Vattikuti Collective Quality Initiative Database Analysis. Urology, 2020, 146, 125-132.	0.5	9
248	The Precision Prostatectomy: "Waiting for Godot― European Urology Focus, 2020, 6, 227-230.	1.6	9
249	Subtotal surgical therapy for localized prostate cancer: a single-center precision prostatectomy experience in 25 patients, and SEER-registry data analysis. Translational Andrology and Urology, 2021, 10, 3155-3166.	0.6	9
250	Gleason 6 Prostate Cancer in One or Two Biopsy Cores Can Harbor More Aggressive Disease. Journal of Endourology, 2011, 25, 699-703.	1.1	8
251	Circulating sex steroids and prostate cancer: introducing the time-dependency theory. World Journal of Urology, 2013, 31, 267-273.	1.2	8
252	Competingâ€risks analysis in patients with T1 squamous cell carcinoma of the penis. BJU International, 2013, 111, E174-9.	1.3	8

#	Article	IF	CITATIONS
253	The Number of Cores at First Biopsy MayÂSuggest the Need for a Confirmatory Biopsy in Patients Eligible for Active Surveillance—Implication for Clinical Decision Making in the Real-life Setting. Urology, 2014, 84, 634-641.	0.5	8
254	An evaluation of the â€~weekend effect' in patients admitted with metastatic prostate cancer. BJU International, 2015, 116, 911-919.	1.3	8
255	The Role of Biomarkers and Genetics in the Diagnosis of Prostate Cancer. European Urology Focus, 2015, 1, 99-108.	1.6	8
256	Impact of Lymphovascular Invasion on Overall Survival in Patients With Prostate Cancer Following Radical Prostatectomy: Stage-per-Stage Analysis. Clinical Genitourinary Cancer, 2021, 19, e319-e325.	0.9	8
257	Management of upper urinary tract urothelial carcinoma. Expert Review of Anticancer Therapy, 2010, 10, 1955-1965.	1.1	7
258	Impact of annual surgical volume on length of stay in patients undergoing minimally invasive prostatectomy: A population-based study. European Journal of Surgical Oncology, 2011, 37, 429-434.	0.5	7
259	The effect of annual surgical caseload on the rates of in-hospital pneumonia and other in-hospital outcomes after radical prostatectomy. International Urology and Nephrology, 2012, 44, 799-806.	0.6	7
260	Intensity-modulated radiation therapy leads to survival benefit only in patients with high-risk prostate cancer: a population-based study. Annals of Oncology, 2014, 25, 979-986.	0.6	7
261	Treatment patterns, testicular loss and disparities in inpatient surgical management of testicular torsion in boys: a populationâ€based study 1998–2010. BJU International, 2016, 118, 969-979.	1.3	7
262	Robot-Assisted Laparoscopic Repair of Extraperitoneal Ureteral Inguinal Hernia with Mesh Placement. Journal of Endourology Case Reports, 2017, 3, 97-100.	0.3	7
263	State-by-state Variation in Prostate-specific Antigen Screening Trends Following the 2011 United States Preventive Services Task Force Panel Update. Urology, 2018, 112, 56-65.	0.5	7
264	Surgically Treated Retroperitoneal Sarcoma: A Population-based Competing Risks Analysis. European Urology Oncology, 2018, 1, 346-351.	2.6	7
265	The Precision Prostatectomy: an IDEAL Stage 0, 1 and 2a Study. BMJ Surgery, Interventions, and Health Technologies, 2019, 1, e000002.	0.6	7
266	Extended pelvic lymphâ€node dissection is independently associated with improved overall survival in patients with prostate cancer at highâ€risk of lymphâ€node invasion. BJU International, 2020, 125, 756-758.	1.3	7
267	A Preoperative Nomogram to Predict Renal Function Insufficiency for Cisplatin-based Adjuvant Chemotherapy Following Minimally Invasive Radical Nephroureterectomy (ROBUUST Collaborative) Tj ETQq1 1	0.7846314	rgBT /Overloc
268	Preoperative circulating sex hormones are not predictors of positive surgical margins at open radical prostatectomy. World Journal of Urology, 2012, 30, 533-539.	1.2	6
269	Predicting the risk of lymph node invasion during radical prostatectomy using the European association of urology guideline nomogram: A validation study. European Journal of Surgical Oncology, 2012, 38, 624-629.	0.5	6
270	Impact of Baseline Characteristics on the Survival Benefit of High-Intensity Local Treatment in Metastatic Urothelial Carcinoma of the Bladder. European Urology Focus, 2018, 4, 568-571.	1.6	6

#	Article	IF	CITATIONS
271	A Nationwide Persistent Underutilization of Adjuvant Radiotherapy in North American Prostate Cancer Patients. Clinical Genitourinary Cancer, 2020, 18, 489-499.e6.	0.9	6
272	An analysis of patients with <scp>T</scp> 2 renal cell carcinoma (<scp>RCC</scp>) according to tumour size: a populationâ€based analysis. BJU International, 2013, 111, 1184-1190.	1.3	5
273	Adjuvant Radiotherapy in Prostate Cancer Patients Treated with Surgery: The Impact of Age and Tumor Characteristics. European Urology Focus, 2015, 1, 191-199.	1.6	5
274	Prevalence of Nonrecommended Screening for Prostate Cancer and Breast Cancer in the United States. JAMA Oncology, 2016, 2, 543.	3.4	5
275	Je le pansai, Dieu le guerit. European Urology, 2017, 72, 343-344.	0.9	5
276	Retziusâ€sparing robotâ€assisted radical prostatectomy. BJU International, 2019, 123, 7-8.	1.3	5
277	Impact of timing on salvage radiation therapy adverse events following radical prostatectomy: A secondary analysis of the RTOG 9601 cohort. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 38.e17-38.e22.	0.8	5
278	Pelvic lymph node dissection at robot-assisted radical prostatectomy: Assessing utilization and nodal metastases within a statewide quality improvement consortium. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 198-203.	0.8	5
279	Evaluation of lymphovascular invasion as a prognostic predictor of overall survival after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 495.e1-495.e6.	0.8	5
280	Prevention and Management of Postprostatectomy Erectile Dysfunction. European Urology Supplements, 2009, 8, 80-87.	0.1	4
281	Re: AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer. European Urology, 2015, 68, 162-163.	0.9	4
282	The diminishing returns of robotic diffusion: complications after robotâ€assisted radical prostatectomy. BJU International, 2016, 117, 211-212.	1.3	4
283	Salvage Radiation Therapy for Biochemical Recurrence After Radical Prostatectomy: Is Earlier Always Better?. Journal of Clinical Oncology, 2017, 35, 1489-1490.	0.8	4
284	Trends in Prostate-Specific Antigen Screening Since the Implementation of the 2012 US Preventive Services Task Force Recommendations. European Urology Focus, 2018, 4, 1002-1004.	1.6	4
285	Re: Follow-up of Prostatectomy Versus Observation for Early Prostate Cancer. European Urology, 2018, 73, 302-303.	0.9	4
286	Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign. Journal of Urology, 2019, 201, 728-734.	0.2	4
287	Surgery and erectile dysfunction. Archivos Espanoles De Urologia, 2010, 63, 640-8.	0.1	4
288	VALIDATION OF THE CRITERIA SUGGESTED BY CURRENT GUIDELINES TO INDICATE THE NEED FOR BASELINE STAGING BONE SCAN IN PATIENTS WITH NEWLY DIAGNOSED PROSTATE CANCER. Journal of Urology, 2009, 181, 782-782.	0.2	3

#	Article	IF	CITATIONS
289	1634 MANAGEMENT OF LOCALIZED KIDNEY CANCER: CALCULATING CANCER-SPECIFIC MORTALITY AND COMPETING-RISKS OF DEATH TRADEOFFS BETWEEN SURGERY AND ACTIVE SURVEILLANCE. Journal of Urology, 2013, 189, .	0.2	3
290	PD43-12 URINARY CONTINENCE OUTCOMES AFTER RETZIUS-SPARING ROBOT-ASSISTED RADICAL PROSTATECTOMY: A PROSPECTIVE, NON-RANDOMIZED, IDEAL STAGE 2B (EXPLORATION) STUDY Journal of Urology, 2016, 195, .	0.2	3
291	MP39-14 IMPACT OF THE 2012 UNITED STATES PREVENTIVE SERVICES TASK FORCE RECOMMENDATION AGAINST PROSTATE SPECIFIC ANTIGEN SCREENING ON PROSTATE CANCER RISK GROUP STRATIFICATION. Journal of Urology, 2016, 195, .	0.2	3
292	MP02-06 EVALUATION OF A GENOMIC CLASSIFIER IN RADICAL PROSTATECTOMY PATIENTS WITH LYMPH NODE METASTASIS. Journal of Urology, 2016, 195, .	0.2	3
293	Surgery-based Multimodal Management of High-risk Prostate Cancer Patients: What Is the Functional Price To Pay for Optimal Disease Control?. European Urology, 2017, 71, 337-339.	0.9	3
294	Surgical Training in the Robotic Surgery Era: The Importance of Structured Programs. European Urology Focus, 2017, 3, 117-118.	1.6	3
295	Oncological and functional efficacy of nephron-sparing surgery versus radical nephrectomy in renal cell carcinoma stages ≥ cT1b: a single institution, matched analysis. Central European Journal of Urology, 2018, 71, 48-57.	0.2	3
296	Impact of treatment modality on overall survival in localized ductal prostate adenocarcinoma: A national cancer database analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 366.e11-366.e18.	0.8	3
297	462. Prevalence and Outcome of Asymptomatic Procedural Patients with COVID-19 Infection. Open Forum Infectious Diseases, 2020, 7, S298-S298.	0.4	3
298	Anti-Androgen Therapy Overcomes the Time Delay in Initiation of Salvage Radiation Therapy and Rescues the Oncological Outcomes in Men with Recurrent Prostate Cancer After Radical Prostatectomy: A Post Hoc Analysis of the RTOG-9601 Trial Data. Annals of Surgical Oncology, 2022, 29, 7206-7215.	0.7	3
299	IS CLIMACTURIA FOLLOWING RADICAL PROSTATECTOMY ASSOCIATED WITH SURGICAL TECHNIQUE?. Journal of Urology, 2008, 179, 515-515.	0.2	2
300	1831 THE NUMBER OF LYMPH NODES REMOVED IN RENAL CELL CARCINOMA DOES AFFECT CANCER SPECIFIC SURVIVAL IN SPECIFIC SUBGROUPS OF PATIENTS: RESULTS FROM A SYSTEMATIC ANALYSIS. Journal of Urology, 2013, 189, .	0.2	2
301	MP51-15 TIME FROM SURGERY TO URINARY CONTINENCE SIGNIFICANTLY INFLUENCES THE SUBSEQUENT RECOVERY OF ERECTILE FUNCTION IN PATIENTS TREATED WITH BILATERAL NERVE-SPARING RADICAL PROSTATECTOMY. Journal of Urology, 2014, 191, .	0.2	2
302	PD12-11 SURVIVAL BENEFIT OF RADICAL PROSTATECTOMY IN PATIENTS WITH CLINICALLY ADVANCED PROSTATE CANCER: ESTIMATIONS OF THE NUMBER NEEDED TO TREAT BASED ON COMPETING-RISKS ANALYSIS. Journal of Urology, 2014, 191, .	0.2	2
303	PD38-12 [11C]CHOLINE PET/CT PREDICTS SURVIVAL IN HORMONE NAÃVE PROSTATE CANCER PATIENTS WITH BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2015, 193, .	0.2	2
304	Reply to Jovo Bogdanović and Vuk Sekulić's Letter to the Editor re: Firas Abdollah, Giorgio Gandaglia, Nazareno Suardi, et al. More Extensive Pelvic Lymph Node Dissection Improves Survival in Patients with Node-positive Prostate Cancer. Eur Urol 2015;67:212–9. European Urology, 2015, 68, e37-e38.	0.9	2
305	PD15-01 THE IMPACT OF 2011 UNITED STATES PREVENTIVE SERVICES TASK FORCE PANEL UPDATE ON PSA SCREENING PRACTICE: A NATIONWIDE, AND STATE-BY-STATE LEVEL ANALYSES Journal of Urology, 2016, 195, .	0.2	2
306	Observational Studies to Contextualize Surgical Trials. European Urology, 2016, 70, 231-232.	0.9	2

#	Article	IF	CITATIONS
307	PD32-05 PROSTATE CANCER SCREENING: EFFECT OF EARLY MEDICAID EXPANSION. Journal of Urology, 2017, 197, .	0.2	2
308	Classification of Partial Nephrectomy as an Outpatient Surgery under CMSÂPart B Reimbursement Program—Does the Evidence JustifyÂtheÂRecommendation?. Urology Practice, 2017, 4, 444-447.	0.2	2
309	The effect of race on survival after local therapy in metastatic prostate cancer patients. Canadian Urological Association Journal, 2018, 13, 175-181.	0.3	2
310	Re: Massimiliano Spaliviero, Nicholas E. Power, Katie S. Murray, et al. Intravenous Mannitol Versus Placebo During Partial Nephrectomy in Patients with Normal Kidney Function: A Double-blind, Clinically-integrated, Randomized Trial. Eur Urol 2018;73:53–9. European Urology, 2018, 74, e48-e49.	0.9	2
311	External validation of genomic classifier-based risk-stratification tool to identify candidates for adjuvant radiation therapy in patients with prostate cancer. World Journal of Urology, 2021, 39, 3217-3222.	1.2	2
312	Predicting lymph node invasion in patients treated with robot-assisted radical prostatectomy. Canadian Journal of Urology, 2016, 23, 8141-50.	0.0	2
313	A novel prognostic model predicting overall survival in patients with metastatic castrationâ€resistant prostate cancer receiving standard chemotherapy: A multiâ€trial cohort analysis. Prostate, 2022, 82, 1293-1303.	1.2	2
314	1038: Erectile Function Following Nerve Sparing Radical Prostatectomy Correlates Well with Post -Operative Penile Length in Flaccidity and at Maximum Erection. Surgical Technique Counts. Journal of Urology, 2007, 177, 343-344.	0.2	1
315	ARE INFERTILE MEN LESS HEALTHY THAN FERTILE MEN? PRELIMINARY RESULTS OF A SURVEY AT A MAJOR TERTIARY ACADEMIC CENTRE. Journal of Urology, 2008, 179, 655-656.	0.2	1
316	Re: Orgasm Associated Incontinence (Climacturia) Following Radical Pelvic Surgery: Rates of Occurrence and Predictors. Journal of Urology, 2008, 180, 1187-1188.	0.2	1
317	DISTRIBUTION OF PELVIC LYMPH NODES IS NOT SYMMETRIC. RESULTS FROM AN EXTENDED PELVIC LYMPH NODE DISSECTION SERIES. Journal of Urology, 2009, 181, 100-101.	0.2	1
318	649 MINIMALLY INVASIVE RADICAL PROSTATECTOMY HOLD NO ADVANTAGE OVER OPEN RADICAL PROSTATECTOMY WITH REGARD TO COMPLICATION RATES: POPULATION-BASED DATA FROM THE UNITED STATES. Journal of Urology, 2011, 185, .	0.2	1
319	982 STAGING LYMPHADENECTOMY IN RENAL CELL CARCINOMA MUST BE EXTENDED: A SENSITIVITY CURVE ANALYSES. Journal of Urology, 2012, 187, .	0.2	1
320	771 SHOULD AN EXTENDED NODAL TEMPLATE FOR HIGH RISK PROSTATE CANCER ALWAYS INCLUDE REMOVAL OF COMMON ILIAC LYMPH NODES?. Journal of Urology, 2012, 187, .	0.2	1
321	774 HEAD-TO-HEAD COMPARISON OF LYMPH NODE DENSITY AND NUMBER OF POSITIVE LYMPH NODES IN STRATIFYING THE OUTCOME OF PATIENTS WITH LYMPH NODE POSITIVE PROSTATE CANCER SUBMITTED TO RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTION. Journal of Urology, 2013, 189,	0.2	1
322	1838 WHEN TO PERFORM LYMPH NODE DISSECTION IN RENAL CELL CARCINOMA PATIENTS: A NOVEL APPROACH TO PREOPERATIVELY ASSESS THE RISK OF LYMPH NODE INVASION AT SURGERY AND NODAL PROGRESSION DURING FOLLOW UP. Journal of Urology, 2013, 189, .	0.2	1
323	961 PREDICTORS OF EARLY BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY AND ADJUVANT RADIOTHERAPY IN MEN WITH PT3NO PROSTATE CANCER. IMPLICATIONS FOR MULTI-MODAL THERAPIES. Journal of Urology, 2013, 189, .	0.2	1
324	Reply to Chris Parker, Matthew R. Sydes and Howard Kynaston's Letter to the Editor re: Firas Abdollah, Nazareno Suardi, Cesare Cozzarini, et al. Selecting the Optimal Candidate for Adjuvant Radiotherapy After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur Urol 2013;63:998–1008. European Urology, 2013, 64, e103-e104.	0.9	1

#	Article	IF	CITATIONS
325	Response to <scp>R</scp> e: Lymph node count threshold for optimal pelvic lymph node staging in prostate cancer. International Journal of Urology, 2013, 20, 845-846.	0.5	1
326	Spatial distribution of positive cores improves the selection of patients with lowâ€risk prostate cancer as candidates for active surveillance. BJU International, 2013, 112, E234-42.	1.3	1
327	Should all men having a radical prostatectomy have a pelvic lymph node dissection? No. Canadian Urological Association Journal, 2013, 4, 425.	0.3	1
328	PD12-12 ADJUVANT RADIOTHERAPY IMPROVES CANCER-SPECIFIC SURVIVAL ONLY IN PATIENTS WITH HIGHLY AGGRESSIVE PROSTATE CANCER. VALIDATION OF RECENTLY RELEASED CRITERIA. Journal of Urology, 2014, 191, .	0.2	1
329	MP32-08 READMISSIONS AFTER MAJOR UROLOGIC CANCER SURGERY. Journal of Urology, 2015, 193, .	0.2	1
330	MP9-08 IMPACT OF SMOKING ON PERIOPERATIVE OUTCOMES AFTER MAJOR UROLOGIC SURGERY. Journal of Urology, 2015, 193, .	0.2	1
331	PD6-12 DIMINISHING RETURNS OF ROBOTIC DIFFUSION: COMPLICATIONS FOLLOWING ROBOT-ASSISTED RADICAL PROSTATECTOMY. Journal of Urology, 2015, 193, .	0.2	1
332	Reply to C.G. Rusthoven et al. Journal of Clinical Oncology, 2015, 33, 1989-1989.	0.8	1
333	MP14-12 EFFICACY OF EARLY AND DELAYED RADIATION IN A PROSTATECTOMY COHORT ADJUSTED FOR GENOMIC AND CLINICAL RISK. Journal of Urology, 2016, 195, .	0.2	1
334	MP21-11 AGE DEPENDENT VARIATION IN THE EFFECT OF PHYSICIAN RECOMMENDATIONS TO UNDERGO PROSTATE SPECIFIC ANTIGEN (PSA) SCREENING FOLLOWING THE UNITED STATES PREVENTIVE SERVICES TASK FORCE 2012 STATEMENT AGAINST PSA SCREENING Journal of Urology, 2016, 195, .	0.2	1
335	PD15-03 DIFFERENCES IN PROSTATE SPECIFIC ANTIGEN TESTING AMONG UROLOGISTS AND PRIMARY CARE PROVIDERS IN THE UNITED STATES FOLLOWING THE 2011 USPSTF RECOMMENDATIONS. Journal of Urology, 2016, 195, .	0.2	1
336	Improved Survival With Local Treatment of Prostate Cancer in Men With Metastatic Disease: Look Before You Leap. Journal of Clinical Oncology, 2017, 35, 914-915.	0.8	1
337	Androgen Deprivation Therapy and Dose-Escalated Radiotherapy for Intermediate- and High-Risk Prostate Cancer. JAMA Oncology, 2017, 3, 280.	3.4	1
338	PD58-12 PSA SCREENING AT THE INTERSECTION OF POLITICS AND POLICY. Journal of Urology, 2017, 197, .	0.2	1
339	Comparing Adjuvant vs Early-Salvage Radiotherapy After Radical Prostatectomy. JAMA Oncology, 2018, 4, 1618.	3.4	1
340	Robotic Urologic Surgery: How to Make an Effective Robotic Program. , 2018, , 77-82.		1
341	Regression Discontinuity Analysis of Salvage Radiotherapy in Prostate Cancer. European Urology Oncology, 2021, 4, 817-820.	2.6	1
342	Adjuvant radiotherapy in prostate cancer patients with positive margins or extracapsular extension. Annals of Translational Medicine, 2019, 7, S291-S291.	0.7	1

#	Article	IF	CITATIONS
343	Re: Timothy J. Wilt, Tien N. Vo, Lisa Langsetmo, et al. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). Eur Urol 2020;77:713–724. European Urology Oncology, 2020, 3, 557-558.	2.6	1
344	Generalizability of Prostate-Specific Antigen (PSA) Screening Trials in a "Real World―Setting: A Nationwide Survey Analysis. Urology, 2021, 148, 1-3.	0.5	1
345	High-intensity local treatment of clinical node-positive urothelial carcinoma of the bladder alongside systemic chemotherapy improves overall survival. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 62.e1-62.e11.	0.8	1
346	The Impact of the Price Transparency Mandate on Cost Reporting for Common Urological Services across the U.S. News Top 21 Hospitals. Urology Practice, 0, , .	0.2	1
347	Comparative effectiveness of radical cystectomy versus bladder-sparing treatment for muscle-invasive urothelial carcinoma: A population-based report Journal of Clinical Oncology, 2014, 32, 334-334.	0.8	1
348	Development and validation of genomic signature to predict ADT treatment failure Journal of Clinical Oncology, 2016, 34, 5018-5018.	0.8	1
349	Using adjuvant radiotherapy to improve cancer-specific survival in patients with highly aggressive prostate cancer: Examining recently released criteria Journal of Clinical Oncology, 2014, 32, 30-30.	0.8	1
350	Population-based comparison of surgical margin status for robotic versus open radical prostatectomy Journal of Clinical Oncology, 2014, 32, 51-51.	0.8	1
351	The Technique of Robotic Nerve-Sparing Prostatectomy. , 2016, , 315-326.		1
352	Efficacy of local treatment in patients with prostate cancer with clinically pelvic lymph node-positive disease at initial diagnosis Journal of Clinical Oncology, 2017, 35, 164-164.	0.8	1
353	Pentafecta for Radical Nephroureterectomy in Patients with High-Risk Upper Tract Urothelial Carcinoma: A Proposal for Standardization of Quality Care Metrics. Cancers, 2022, 14, 1781.	1.7	1
354	Risk-based assessment of the impact of intravesical therapy on recurrence-free survival rate following resection of suspected low-grade, non-muscle-invasive bladder cancer (NMIBC): a Southwest Oncology Groups (SWOG) S0337 post-hoc analysis. Clinical Genitourinary Cancer, 2022, , .	0.9	1
355	IS DIABETES MELLITUS ASSOCIATED WITH POORLY DIFFERENTIATED PROSTATE CANCER (PCa)?. Journal of Urology, 2008, 179, 65-65.	0.2	0
356	IS SPERM CRYOPRESERVATION BEFORE SURGICAL TREATMENT OF INTEREST IN UROLOGIC CANCER PATIENTS?. Journal of Urology, 2008, 179, 597-597.	0.2	0
357	CAN 24 CORES TRANS-RECTAL SATURATION BIOPSY IDENTIFY UNILATERAL PROSTATE CANCER POTENTIALLY AMENABLE TO FOCAL TREATMENT?. Journal of Urology, 2009, 181, 103-104.	0.2	0
358	ISOLATED BLADDER NECK INVOLVEMENT FROM PROSTATE CANCER SHOULD NOT BE CONSIDERED AS PT4 DISEASE. Journal of Urology, 2009, 181, 290-291.	0.2	0
359	TIME FROM PROSTATE BIOPSY TO RADICAL PROSTATECTOMY REPRESENTS AN INDEPENDENT PREDICTOR OF PROSTATE CANCER SIGNIFICANT UPGRADING. Journal of Urology, 2009, 181, 56-56.	0.2	0
360	PERCENTAGE OF POSITIVE CORES STRONGLY INFLUENCES THE RATE OF GLEASON SUM AGREEMENT BETWEEN PROSTATE BIOPSY AND RADICAL PROSTATECTOMY. Journal of Urology, 2009, 181, 754-754.	0.2	0

#	Article	IF	CITATIONS
361	SHOULD SEPTA- AND OCTOGENARIAN PATIENTS WITH PROSTATE CANCER BE TREATED WITH RADICAL PROSTATECTOMY?. Journal of Urology, 2009, 181, 206-207.	0.2	0
362	DEVELOPMENT AND SPLIT SAMPLE VALIDATION OF AN UPDATED NOMOGRAM PREDICTING THE PROBABILITY OF LYMPH NODE INVASION IN PATIENTS WITH CLINICALLY LOCALIZED PROSTATE CANCER UNDERGOING EXTENDED PELVIC LYMPH NODE DISSECTION. Journal of Urology, 2009, 181, 757-757.	0.2	0
363	COMPARISON BETWEEN TRANSRECTAL AND TRANSPERINEAL PROSTATE CANCER DETECTION RATE AT SATURATION BIOPSY AFTER PREVIOUS NEGATIVE BIOPSIES. RESULTS OF A TWO-INSTITUTION EXPERIENCE. Journal of Urology, 2009, 181, 709.	0.2	0
364	1801 IMPACT OF LYMPH NODE DENSITY ON CANCER-SPECIFIC SURVIVAL IN PATIENTS WITH NODE-POSITIVE RENAL CELL CARCINOMA. Journal of Urology, 2010, 183, .	0.2	0
365	652 ARE TESTICULAR PROSTHESES OF INTEREST TO PATIENTS TREATED WITH ORCHIECTOMY FOR GERM-CELL TESTICULAR CANCER?. Journal of Urology, 2010, 183, .	0.2	0
366	932 THERE IS NO WAY TO IDENTIFY PATIENTS WHO WILL HARBOR PT2A PROSTATE CANCER AT RADICAL PROSTATECTOMY. IMPLICATIONS FOR FOCAL THERAPIES. Journal of Urology, 2010, 183, .	0.2	0
367	395 ASSESSING THE RISK OF LYMPH NODE INVASION IN PATIENTS WITH INTERMEDIATE RISK PROSTATE CANCER. A NOVEL PREDICTION TOOL. Journal of Urology, 2010, 183, .	0.2	0
368	1742 OUTCOME OF PATIENTS POTENTIALLY SUITABLE FOR ACTIVE SURVEILLANCE UNDERGOING RADICAL PROSTATECTOMY AS FIRST TREATMENT CHOICE. RESULTS OF INTERMEDIATE-TERM FOLLOW-UP. Journal of Urology, 2010, 183, .	0.2	0
369	930 AGE ADJUSTED VALIDATION OF THE MOST STRINGENT CRITERIA FOR ACTIVE SURVELLIANCE: IMPLICATIONS FOR PATIENT SELECTION. Journal of Urology, 2010, 183, .	0.2	Ο
370	1848 THE ACCURACY OF THE PERCENTAGE OF POSITIVE CORES IN PREDICTING ADVANCED PROSTATE CANCER DOES NOT CHANGE ACCORDING TO THE EXTENT OF BIOPSY SCHEME. Journal of Urology, 2010, 183, .	0.2	0
371	655 IMPORTANT RACIAL DISPARITY EXISTS WITH RESPECT TO THE USE OF MINIMALLY INVASIVE RADICAL PROSTATECTOMY IN THE UNITED STATES. Journal of Urology, 2011, 185, .	0.2	0
372	1670 NON-CANCER RELATED MORTALITY IN PARTIAL VERSUS RADICAL NEPHRECTOMY FOR T1A RENAL CELL CARCINOMA: A PROPENSITY-BASED MATCHED ANALYSIS. Journal of Urology, 2011, 185, .	0.2	0
373	1845 RATES OF CONTINENT URINARY DIVERSION AFTER RADICAL CYSTECTOMY: IS THERE A PLACE FOR IMPROVEMENT?. Journal of Urology, 2011, 185, .	0.2	0
374	1841 THE IMPORTANCE OF PELVIC LYMPH NODE DISSECTION IN THE ELDERLY: IMPLICATIONS FOR INTERPRETATION OF THE 2010 NATIONAL COMPREHENSIVE CANCER NETWORK PRACTICE GUIDELINES FOR BLADDER CANCER TREATMENT. Journal of Urology, 2011, 185, .	0.2	0
375	479 OPEN RADICAL PROSTATECTOMY IN THE ELDERLY: A CASE FOR CONCERN?. Journal of Urology, 2011, 185, .	0.2	0
376	1926 PREDICTING FACTORS FOR INSIGNIFICANT CANCER AFTER A DIAGNOSIS OF ONE SINGLE MINUTE FOCUS OF PROSTATE CANCER ON NEEDLE BIOPSY. Journal of Urology, 2011, 185, .	0.2	0
377	1642 PELVIC LYMPH NODE DISSECTION IS PERFORMED LESS FREQUENTLY IN PATIENTS TREATED WITH MINIMALLY INVASIVE RADICAL PROSTATECTOMY. Journal of Urology, 2011, 185, .	0.2	0
378	543 TREATMENT MANAGEMENT OF T1A RENAL CELL CARCINOMA IN THE 21ST CENTURY: A POPULATION-BASED ANALYSIS. Journal of Urology, 2011, 185, .	0.2	0

#	Article	IF	CITATIONS
379	1844 ACCURACY OF THE CHARLSON COMORBIDITY INDEX (CCI) IN PREDICTING IN-HOSPITAL MORTALITY (IHM) IN PATIENTS TREATED WITH RADICAL CYSTECTOMY (RC). Journal of Urology, 2011, 185, .	0.2	0
380	44 BLADDER CANCER CONTROL OUTCOMES HAVE NOT IMPROVED WITHIN THE LAST THIRTY YEARS: A TREND ANALYSIS IN THE UNITED STATES. Journal of Urology, 2011, 185, .	0.2	0
381	1901 ADVANCED AGE IS AN INDEPENDENT PREDICTOR OF CANCER-SPECIFIC MORTALITY AFTER RADICAL CYSTECTOMY FOR UROTHELIAL CARCINOMA OF THE URINARY BLADDER: A COMPETING-RISKS REGRESSION ANALYSIS. Journal of Urology, 2011, 185, .	0.2	0
382	658 RATES OF HOSPITAL AQUIRED PNEUMONIA AFTER OPEN RADICAL PROSTATECTOMY DECLINED IN THE LAST DECADE. Journal of Urology, 2011, 185, .	0.2	0
383	475 OPEN RADICAL PROSTATECTOMY PERFORMED BY LOW VOLUME SURGEONS PREDISPOSES TO HIGHER RATES OF RECTAL LACERATION. Journal of Urology, 2011, 185, .	0.2	0
384	Reply to Charles B. Simone II, Charles B. Simone's Letter to the Editor re: Firas Abdollah, Maxine Sun, Rodolphe Thuret, et al. A Competing-Risks Analysis of Survival After Alternative Treatment Modalities for Prostate Cancer Patients: 1988–2006. Eur Urol 2011;59:88–95. European Urology, 2011, 59, e31-e32.	0.9	0
385	Clinical experience and critical evaluation of the role of everolimus in advanced renal cell carcinoma. Open Access Journal of Urology, 2011, 3, 43.	0.3	0
386	In Reply to Yu. International Journal of Radiation Oncology Biology Physics, 2012, 84, 301-302.	0.4	0
387	178 A SINGLE SPOT AT [(11)C]CHOLINE-PET/CT SCAN IS NOT PREDICTIVE OF A SINGLE, ISOLATED NODAL METASTASIS AT FINAL PATHOLOGY. IMPLICATIONS FOR SALVAGE TREATMENTS. Journal of Urology, 2012, 187, .	0.2	0
388	180 [11C]CHOLINE PET/CT SCAN PREDICTS SURVIVAL IN PROSTATE CANCER PATIENTS WITH BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2012, 187, .	0.2	0
389	182 EVALUATION OF LYMPH NODE RECURRENT PROSTATE CANCER WITH INTEGRATED [11C]CHOLINE PET/CT IN PATIENTS WITH PSA FAILURE AFTER RADICAL PROSTATECTOMY: VALIDATION BY HISTOLOGICAL ANALYSIS. Journal of Urology, 2012, 187, .	0.2	0
390	185 MODELS ASSESSING THE NEED FOR PELVIC LYMPH NODE DISSECTION CANNOT BE RELIABLY USED IN MEN WITH PROSTATE CANCER PREVIOUSLY TREATED WITH SURGERY FOR BENIGN PROSTATIC ENLARGEMENT. Journal of Urology, 2012, 187, .	0.2	0
391	186 THE 2011 NATIONAL COMPREHENSIVE CANCER NETWORK GUIDELINES RECOMMENDATIONS FOR PELVIC LYMPH NODE DISSECTION IN PROSTATE CANCER PATIENTS ARE NOT ACCURATE. A PLEA FOR RENEWAL. Journal of Urology, 2012, 187, .	0.2	0
392	187 IS [11C]CHOLINE PET/CT RECOMMENDED FOR RESTAGING PROSTATE CANCER PATIENTS AFTER RADICAL PROSTATECTOMY WHEN PSA IS LOWER THAN 1 NG/ML?. Journal of Urology, 2012, 187, .	0.2	0
393	365 IDENTIFYING PATIENTS AT REAL RISK OF DYING FROM PROSTATE CANCER. A NOVEL RISK SCORE FOR THE SELECTION OF CANDIDATES FOR ADJUVANT RADIATION THERAPY. Journal of Urology, 2012, 187, .	0.2	0
394	370 DEVELOPMENT AND INTERNAL VALIDATION OF A PROSTATE HEALTH INDEX (PHI) BASED NOMOGRAM FOR PREDICTING PROSTATE CANCER AT INITIAL EXTENDED BIOPSY. Journal of Urology, 2012, 187, .	0.2	0
395	570 AN ANALYSIS OF PATIENTS WITH T2 RENAL CELL CARCINOMA ACCORDING TO TUMOR SIZE: A POPULATION-BASED ANALYSIS. Journal of Urology, 2012, 187, .	0.2	0
396	663 ADJUVANT RADIOTHERAPY NEGATIVELY IMPACTS ON THE LONG-TERM RECOVERY OF NORMAL SEXUAL FUNCTION IN TESTICULAR GERM-CELL CANCER SURVIVORS. Journal of Urology, 2012, 187, .	0.2	0

#	Article	IF	CITATIONS
397	768 DO NODAL METASTASES INVARIABLY IMPACT ON SURVIVAL OF PATIENTS WITH PROSTATE CANCER? IMPORTANCE OF LOCAL DISEASE STATUS. Journal of Urology, 2012, 187, .	0.2	0
398	770 A SINGLE POSITIVE LYMPH NODE HAS NO DETRIMENTAL EFFECT ON SURVIVAL OF PATIENTS WITH PROSTATE CANCER TREATED WITH EXTENDED PELVIC LYMPH NODE DISSECTION. RESULTS OF A MATCHED CONTROLLED ANALYSIS. Journal of Urology, 2012, 187, .	0.2	0
399	772 PREDICTORS OF LONG-TERM SURVIVAL OF PATIENTS WITH HIGH VOLUME OF NODAL METASTASES AT EXTENDED PELVIC LYMPH NODE DISSECTION FOR PROSTATE CANCER. THE IMPORTANCE OF AN INTEGRATED, MULTIMODAL APPROACH. Journal of Urology, 2012, 187, .	0.2	0
400	2233 AN INITIAL SERUM PSA LEVEL LESS THAN 5 NG/ML AT DIAGNOSIS DOES NOT CORRELATE WITH TUMOR VOLUME IN LOW RISK PROSTATE CANCER PATIENTS. IMPLICATIONS FOR CONSERVATIVE TREATMENTS. Journal of Urology, 2012, 187, .	0.2	0
401	1125 A NOVEL TOOL FOR THE PREDICTION OF URINARY INCONTINENCE AFTER BILATERAL NERVE SPARING RADICAL PROSTATECTOMY. Journal of Urology, 2012, 187, .	0.2	0
402	1400 CLINICAL NODAL STAGING SCORES FOR BLADDER CANCER A NEW PREOPERATIVELY NODAL ASSESSMENT TOOL. Journal of Urology, 2012, 187, .	0.2	0
403	2204 HOW TO EXPAND INDICATIONS FOR ACTIVE SURVEILLANCE WITHOUT COMPROMISING CANCER CONTROL. THE IMPORTANCE OF THE EXTENT OF BIOPSY SAMPLING. Journal of Urology, 2012, 187, .	0.2	0
404	1126 THE EFFECT OF PREOPERATIVE CANCER AGGRESSIVENESS ON LEARNING CURVE AMONG HIGH VOLUME SURGEONS PERFORMING RADICAL RETROPUBIC PROSTATECTOMY. Journal of Urology, 2012, 187, .	0.2	0
405	1379 THE KEY ROLE OF TIME IN PREDICTING POST-RADICAL PROSTATECTOMY ERECTILE FUNCTION RECOVERY: CONDITIONAL SURVIVAL ANALYSES. Journal of Urology, 2012, 187, .	0.2	0
406	2066 MISCLASSIFICATION OF MICRO-FOCUS PROSTATE CANCER DECREASES WITH THE EXTENT OF BIOPSY SAMPLING. IMPORTANCE OF ACCURATE DETECTION. Journal of Urology, 2012, 187, .	0.2	0
407	1147 IS THE WEB CHANGING THE RELATIONSHIP BETWEEN THE CLINICIANS AND THE URO-ANDROLOGICAL PATIENTS? RESULTS OF AN EXPLORATORY ANALYSIS. Journal of Urology, 2012, 187, .	0.2	0
408	1685 HIGHER PERIOPERATIVE MORBIDITY AND IN-HOSPITAL MORTALITY IN PATIENTS WITH END STAGE RENAL DISEASE UNDERGOING NEPHRECTOMY FOR NON-METASTATIC KIDNEY CANCER: A POPULATION-BASED ANALYSIS. Journal of Urology, 2012, 187, .	0.2	0
409	2111 SERUM SEX STEROIDS DEPICT A NON LINEAR U-SHAPED ASSOCIATION WITH HIGH RISK PROSTATE CANCER AT RADICAL PROSTATECTOMY - IMPLICATIONS FOR INDIVIDUALIZED HORMONAL THERAPY. Journal of Urology, 2012, 187, .	0.2	0
410	Reply to Michael Froehner's Letter to the Editor re: Firas Abdollah, Maxine Sun, Jan Schmitges, et al. Cancer-Specific and Other-Cause Mortality After Radical Prostatectomy Versus Observation in Patients with Prostate Cancer: Competing-Risks Analysis of a Large North American Population-Based Cohort. Eur Urol 2011;60:920–30. European Urology, 2012, 61, e12.	0.9	0
411	372 THE NUMBER OF POSITIVE NODES IS THE STRONGEST PREDICTOR OF CANCER SPECIFIC SURVIVAL IN PATIENTS TREATED WITH RADICAL PROSTATECTOMY FOR PATHOLOGICAL T3 PROSTATE CANCER. Journal of Urology, 2013, 189, .	0.2	0
412	2235 THE NUMBER OF BIOPSY CORES TAKEN IS A MAJOR PREDICTOR OF UNFAVORABLE PROSTATE CANCER AT FINAL PATHOLOGY IN PATIENTS CANDIDATE FOR ACTIVE SURVEILLANCE: CLINICAL IMPLICATIONS. Journal of Urology, 2013, 189, .	0.2	0
413	962 PREDICTION OF LONG-TERM CANCER RECURRENCE AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH LYMPH NODE INVASION: RESULTS OF CONDITIONAL SURVIVAL ANALYSES. Journal of Urology, 2013, 189, .	0.2	0
414	340 LONG TERM DIABETES MELLITUS INCREASES THE RISK OF POORLY DIFFERENTIATED TUMOR IN PROSTATE CANCER PATIENTS. Journal of Urology, 2013, 189, .	0.2	0

#	Article	IF	CITATIONS
415	776 ASSOCIATION BETWEEN TIME TO BIOCHEMICAL RECURRENCE AND CANCER SPECIFIC AND OTHER CAUSE MORTALITY IN MEN WITH HIGH RISK PROSTATE CANCER TREATED WITH RADICAL PROSTATECTOMY WITHOUT ADJUVANT TREATMENTS. A MULTI-INSTITUTIONAL ANALYSIS. Journal of Urology, 2013, 189, .	0.2	0
416	247 SPATIAL DISTRIBUTION OF POSITIVE CORES DECREASES MISCLASSIFICATION RATES OF PATIENTS WITH LOW RISK PROSTATE CANCER CANDIDATE FOR ACTIVE SURVEILLANCE. Journal of Urology, 2013, 189, .	0.2	0
417	1457 A USER-FRIENDLY CLINICAL ALGORITHM AND NOMOGRAM, BASED ON PADUA SCORE, BMI AND CHARLSON CO-MORBIDITY INDEX, TO PREDICT PERIOPERATIVE COMPLICATIONS IN RENAL CELL CARCINOMA PATIENTS UNDERGOING NEPHRON SPARING SURGERY. Journal of Urology, 2013, 189, .	0.2	0
418	2224 HEAD-TO-HEAD COMPARISON OF PROSTATE HEALTH INDEX AND URINARY PCA3 ASSAY IN PREDICTING PROSTATE CANCER AT INITIAL OR REPEAT PROSTATE BIOPSY. Journal of Urology, 2013, 189, .	0.2	0
419	Response to <scp>R</scp> e: Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: A populationâ€based analysis. International Journal of Urology, 2013, 20, 548-549.	0.5	0
420	In reply to the letter to the editor â€~in Reply to Gandaglia et al.' by De Bari et al Annals of Oncology, 2014, 25, 1862-1863.	0.6	0
421	MP37-20 INDIVIDUAL SURGEON COMMITMENT TO PELVIC LYMPH NODE DISSECTION RATHER THAN SURGICAL VOLUME IS A MAJOR DETERMINANT OF THE EXTENT OF NODAL DISSECTION DURING ROBOT-ASSISTED RADICAL PROSTATECTOMY. Journal of Urology, 2014, 191, .	0.2	0
422	PD15-09 PELVIC LYMPH NODE DISSECTION CAN BE SAFELY OMITTED IN MEN WITH A RISK OF NODAL METASTASES ≧% BASED ON THE BRIGANTI NOMOGRAM: VALIDATION OF THE EAU GUIDELINS RECCOMENDATIONS FOR NODAL DISSECTION BASED ON PATIENT OUTCOME. Journal of Urology, 2014, 191,	0.2	0
423	OP3-06 IMPACT OF TIME TO BIOCHEMICAL RECURRENCE ON CANCER-SPECIFIC MORTALITY IN PATIENTS WITH HIGH-RISK PROSTATE CANCER TREATED WITH RADICAL PROSTATECTOMY: A COMPETING-RISKS REGRESSION ANALYSIS. Journal of Urology, 2014, 191, .	0.2	0
424	MP37-02 IMPACT OF SURGICAL VOLUME ON SURGICAL MARGIN STATUS IN PATIENTS TREATED WITH ROBOT-ASSISTED RADICAL PROSTATECTOMY. Journal of Urology, 2014, 191, .	0.2	0
425	PD15-08 A MORE EXTENSIVE PELVIC LYMPH NODE DISSECTION IS ASSOCIATED WITH IMPROVED SURVIVAL OF PATIENTS WITH NODE POSITIVE PROSTATE CANCER. Journal of Urology, 2014, 191, .	0.2	0
426	MP61-06 NEOADJUVANT CHEMOTHERAPY IS NOT ASSOCIATED WITH WORSE SHORT-TERM OUTCOMES IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER UNDERGOING RADICAL CYSTECTOMY: A POPULATION-BASED STUDY. Journal of Urology, 2014, 191, .	0.2	0
427	PD14-09 THE IMPACT OF ROBOTIC-ASSISTED RADICAL PROSTATECTOMY ON THE USE AND EXTENT OF PELVIC LYMPH NODE DISSECTION IN THE "POST-LEARNING CURVE―ERA. Journal of Urology, 2014, 191, .	0.2	0
428	PD12-04 THE EFFECT OF AGE AT DIAGNOSIS ON PROSTATE CANCER MORTALITY: A GRADE-FOR-GRADE AND STAGE-FOR-STAGE ANALYSIS. Journal of Urology, 2014, 191, .	0.2	0
429	Editorial Comment. Journal of Urology, 2014, 192, 95-95.	0.2	0
430	MP69-01 CAN WE CONSIDER PATIENTS WITH LIMITED BIOPSY GLEASON SCORE 3+4 ELIGIBLE FOR ACTIVE SURVEILLANCE?. Journal of Urology, 2014, 191, .	0.2	0
431	MP69-18 HOW TO EXPAND INDICATIONS FOR ACTIVE SURVEILLANCE WITHOUT COMPROMISING CANCER CONTROL: A SYSTEMATIC ASSESSMENT OF THE CURRENTLY USED CRITERIA FOR PROSTATE CANCER PATIENTS. Journal of Urology, 2014, 191, .	0.2	0
432	MP24-06 THE IMPACT OF INSURANCE STATUS ON TUMOR CHARACTERISTICS AND TREATMENT SELECTION IN CONTEMPORARY PROSTATE CANCER PATIENTS. Journal of Urology, 2015, 193, .	0.2	0

#	Article	IF	CITATIONS
433	MP4-16 PATTERNS OF CLINICAL RECURRENCE AND IMPACT OF SITEÂOFÂMETASTASIS ON MORTALITY OF PATIENTS WITH NODEÂPOSITIVE PROSTATE CANCER AFTER RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTION. Journal of Urology, 2015, 193, .	0.2	0
434	MP64-13 HEALTHCARE-ASSOCIATED INFECTIONS FOLLOWING CYSTECTOMY: ROOM FOR IMPROVEMENT. Journal of Urology, 2015, 193, .	0.2	0
435	MP77-10 THE INFLUENCE OF PHYSICIAN RECOMMENDATION ON PSA SCREENING. Journal of Urology, 2015, 193, .	0.2	0
436	MP56-16 VERY LONG TERM OUTCOMES OF RADICAL PROSTATECTOMY IN PATIENTS WITH CLINICALLY LOCALIZED PROSTATE CANCER. RESULTS FROM A SINGLE INSTITUTION SERIES. Journal of Urology, 2015, 193, .	0.2	0
437	MP65-19 AN EVALUATION OF THE TIMING OF SURGICAL COMPLICATIONS FOLLOWING RADICAL CYSTECTOMY. Journal of Urology, 2015, 193, .	0.2	0
438	PD38-01 HETEROGENEITY OF RECOMMENDED PSA SCREENING PRACTICES IN MEN AGED 55-69 IN THE UNITED STATES. Journal of Urology, 2015, 193, .	0.2	0
439	MP48-13 IDENTIFICATION OF PATHOLOGICALLY FAVORABLE DISEASE IN INTERMEDIATE RISK PROSTATE CANCER PATIENTS: IMPLICATIONS FOR SELECTION OF ACTIVE SURVEILLANCE CANDIDATES. Journal of Urology, 2015, 193, .	0.2	0
440	PD30-03 PREDICTING UNFAVORABLE PROSTATE CANCER IN ACTIVE SURVEILLANCE CANDIDATES TREATED WITH RADICAL PROSTATECTOMY: A POPULATION-BASED STUDY. Journal of Urology, 2015, 193, .	0.2	0
441	MP56-05 EARLY POST-OPERATIVE PSA AFTER RADICAL PROSTATECTOMY IS A MAJOR PREDICTOR OF PROGRESSION AND DEATH IN PATIENTS WITH LYMPH NODE METASTASES. RESULTS FROM A TERTIARY CARE CENTER. Journal of Urology, 2015, 193, .	0.2	0
442	MP9-14 POSTOPERATIVE SEPSIS PREDICTION IN PATIENTS UNDERGOING MAJOR CANCER SURGERY. Journal of Urology, 2015, 193, .	0.2	0
443	MP82-02 LONG-TERM OUTCOMES OF PATIENTS WITH SEMINAL VESICLE INVASION AT RADICAL PROSTATECTOMY: THE IMPORTANCE OF A MULTIMODAL APPROACH TO INCREASE PATIENT SURVIVAL. Journal of Urology, 2015, 193, .	0.2	0
444	MP4-14 LONG-TERM CANCER CONTROL OUTCOMES IN PROSTATE CANCER (PCA) PATIENTS TREATED WITH ROBOTIC-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY (RALP): A MULTI-INSTITUTIONAL DATABASE ANALYSIS Journal of Urology, 2015, 193, .	0.2	0
445	PD30-12 RACIAL DISPARITIES IN THE SURGICAL CARE OF LOCALIZED PROSTATE CANCER. Journal of Urology, 2015, 193, .	0.2	0
446	MP59-03 AN EVALUATION OF THE TIMING OF SURGICAL COMPLICATIONS FOLLOWING NEPHRECTOMY. Journal of Urology, 2015, 193, .	0.2	0
447	MP82-07 DOES LOCAL TREATMENT OF THE PRIMARY TUMOR IMPROVE SURVIVAL OF METASTATIC PROSTATE CANCER PATIENTS? RESULTS FROM A POPULATION-BASED STUDY Journal of Urology, 2015, 193, .	0.2	0
448	PD30-09 THE EFFECT OF ANDROGEN DEPRIVATION THERAPY FOR LOCALIZED PROSTATE CANCER ON CARDIOVASCULAR MORBIDITY ACCORDING TO LIFE EXPECTANCY. Journal of Urology, 2015, 193, .	0.2	0
449	MP54-07 INCIDENCE, ADMISSION RATES AND ECONOMIC BURDEN OF PEDIATRIC EMERGENCY DEPARTMENT VISITS FOR URINARY TRACT INFECTION. Journal of Urology, 2015, 193, .	0.2	0
450	MP78-15 BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY: WHO IS AT RISK OF DYING FROM PROSTATE CANCER?. Journal of Urology, 2015, 193, .	0.2	0

#	Article	IF	CITATIONS
451	MP79-04 NATIONAL TRENDS AND RACIAL DISPARITIES IN LIVING KIDNEY DONATION: ANALYSIS OF THE UNITED NETWORK OF ORGAN SHARING 1998-2011. Journal of Urology, 2015, 193, .	0.2	0
452	MP77-13 DEFICIENCIES IN PSA SCREENING PRACTICES IN BLACK MEN AGED 55-69 IN THE UNITED STATES. Journal of Urology, 2015, 193, .	0.2	0
453	PD38-06 UNDERSTANDING THE USE OF PROSTATE BIOPSY AMONG MEN WITH LIMITED LIFE EXPECTANCY. Journal of Urology, 2015, 193, .	0.2	0
454	MP73-11 ANDROGEN DEPRIVATION THERAPY AND INCREASED NON-CANCER MORTALITY IN PROSTATE CANCER PATIENTS: ANALYSIS OF THE NUMBER NEEDED TO TREAT. Journal of Urology, 2015, 193, .	0.2	0
455	PD32-09 VERY LONG-TERM ONCOLOGICAL OUTCOMES OF PATIENTS TREATED WITH RADICAL PROSTATECTOMY FOR NODE POSITIVE PROSTATE CANCER: A MULTI-INSTITUTIONAL, CONDITIONAL SURVIVAL ANALYSIS. Journal of Urology, 2015, 193, .	0.2	0
456	MP67-05 THE IMPACT OF PREOPERATIVE HYPOALBUMINEMIA ON PERIOPERATIVE OUTCOMES AFTER RADICAL CYSTECTOMY INÂ1,262 PATIENTS. Journal of Urology, 2015, 193, .	0.2	0
457	MP87-05 INCREASING USE OF HOSPICE SERVICES FOR METASTATIC PROSTATE CANCER MODERATES THE ECONOMIC BURDEN OFÂHOSPITAL ADMISSIONS FOR METASTATIC PROSTATE CANCER. Journal of Urology, 2015, 193, .	0.2	0
458	MP56-18 NON-SURGICALLY RELATED CAUSES OF ERECTILE DYSFUNCTION AFTER BILATERAL NERVE SPARING RADICAL PROSTATECTOMY: RESULTS FROM A SINGLE INSTITUTION SERIES. Journal of Urology, 2015, 193, .	0.2	0
459	MP60-01 PREVALENCE OF NON-RECOMMENDED SCREENING FOR PROSTATE CANCER AND BREAST CANCER IN THE UNITED STATES. Journal of Urology, 2015, 193, .	0.2	0
460	MP78-01 CONTEMPORARY MANAGEMENT OF PROSTATE CANCER PATIENTS SUITABLE FOR ACTIVE SURVEILLANCE: A POPULATION-BASED STUDY Journal of Urology, 2015, 193, .	0.2	0
461	MP77-12 CONTEMPORARY PATTERNS OF SELF-REPORTED PSA SCREENING IN U.S. VETERANS. Journal of Urology, 2015, 193, .	0.2	0
462	MP62-01 FUNCTIONAL OUTCOMES IN PATIENTS WITH CLINICALLY HIGH-RISK PROSTATE CANCER (PCA) TREATED WITH ROBOT-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY (RALP). Journal of Urology, 2015, 193, .	0.2	0
463	MP78-19 PREDICTING PATHOLOGIC OUTCOMES IN PATIENTS UNDERGOING ROBOT-ASSISTED RADICAL PROSTATECTOMY FOR HIGH-RISK PROSTATE CANCER: A PREOPERATIVE NOMOGRAM. Journal of Urology, 2015, 193, .	0.2	0
464	PD30-08 CANCER-CONTROL OUTCOMES IN PATIENTS WITH CLINICALLY HIGH-RISK PROSTATE CANCER (PCA) TREATED WITH ROBOTIC-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY (RALP): A MULTI-INSTITUTIONAL DATABASE ANALYSIS. Journal of Urology, 2015, 193, .	0.2	0
465	MP87-14 ADJUVANT RADIOTHERAPY IN PROSTATE CANCER PATIENTS TREATED WITH SURGERY: THE IMPACT OF AGE AND TUMOR CHARACTERISTICS. Journal of Urology, 2015, 193, .	0.2	0
466	MP73-19 PRIMARY ANDROGEN DEPRIVATION THERAPY INCREASES ALL CAUSE MORTALITY IN POPULATIONS MATCHED BY COMORBIDITY ADJUSTED LIFE EXPECTANCY AND DISEASE RISK. Journal of Urology, 2015, 193, .	0.2	0
467	The Authors Respond. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 117.2-122.	2.3	0
468	The importance of frailty: Know thy patient. BJU International, 2016, 117, 716-717.	1.3	0

#	Article	IF	CITATIONS
469	MP37-02 INFORMED DECISION-MAKING FOR PROSTATE-SPECIFIC ANTIGEN SCREENING. Journal of Urology, 2016, 195, .	0.2	0
470	MP07-20 DEVELOPMENT AND VALIDATION OF GENOMIC SIGNATURE THAT PREDICTS ADT TREATMENT FAILURE. Journal of Urology, 2016, 195, .	0.2	0
471	Reply to Michael Froehner, Rainer Koch, Manfred P. Wirth's Letter to the Editor re: Jesse D. Sammon, Firas Abdollah, Anthony D'Amico, et al. Predicting Life Expectancy in Men Diagnosed with Prostate Cancer. Eur Urol 2015;68:756–65. European Urology, 2016, 69, e129.	0.9	0
472	MP80-20 LONG-TERM FUNCTIONAL OUTCOMES OF PROSTATE CANCER PATIENTS TREATED WITH ROBOT-ASSISTED RADICAL PROSTATECTOMY. Journal of Urology, 2016, 195, .	0.2	0
473	PD37-03 IS THE PROSTATE CANCER INTERVENTION VERSUS OBSERVATION TRIAL REFLECTIVE OF THE CONTEMPORARY USÂPOPULATION DIAGNOSED WITH PROSTATE CANCER? RESULTS FROM THE NATIONAL CANCER DATABASE 2004-2011. Journal of Urology, 2016, 195, .	0.2	0
474	MP21-07 THE AFFORDABLE CARE ACT AND PSA SCREENING PRACTICES: ANALYSIS OF RACIAL SUBGROUPS. Journal of Urology, 2016, 195, .	0.2	0
475	The importance of adjuvant therapy in patients with node-positive prostate cancer: A nationwide validation study. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 577-578.	0.8	0
476	PI-04 SURGEON AND HOSPITAL VARIATION IN THE COSTS OF ROBOT-ASSISTED RADICAL PROSTATECTOMY IN THE UNITED STATES. Journal of Urology, 2016, 195, .	0.2	0
477	MP07-07 PREDICTING ADVERSE PATHOLOGICAL OUTCOMES IN PROSTATE CANCER (PCA) PATIENTS UNDERGOING RADICAL PROSTATECTOMY (RP): THE ROLE OF GENOMIC SIGNATURE Journal of Urology, 2016, 195, .	0.2	0
478	MP25-08 DETERMINANTS OF PROSTATE CANCER SCREENING IN ASIAN AMERICANS. Journal of Urology, 2016, 195, .	0.2	0
479	MP69-11 MINIMALLY INVASIVE VS. OPEN RADICAL PROSTATECTOMY: AN ANALYSIS OF 30-DAY POSTOPERATIVE COMPLICATIONS, UNPLANNED READMISSIONS, AND MORTALITY. Journal of Urology, 2016, 195, .	0.2	0
480	MP21-10 THE IMPACT OF MEDICARE ELIGIBILITY ON PROSTATE CANCER SCREENING BEHAVIORS. Journal of Urology, 2016, 195, .	0.2	0
481	PD37-01 CONTEMPORARY TRENDS IN TREATMENT PATTERNS FORÂMENÂDIAGNOSED WITH CLINICALLY LOCALIZED PROSTATE CANCER. Journal of Urology, 2016, 195, .	0.2	0
482	MP21-05 TEMPORAL TRENDS IN PROSTATE CANCER RISK GROUP STRATIFICATION FOLLOWING THE 2008 UNITED STATES PREVENTIVE SERVICES TASK FORCE RECOMMENDATIONS. Journal of Urology, 2016, 195, .	0.2	0
483	MP80-02 LATE RECOVERY OF ERECTILE FUNCTION IN MEN TREATED WITH ROBOTIC-ASSISTED RADICAL PROSTATECTOMY: A NOVEL NOMOGRAM DEVELOPMENT AND VALIDATION. Journal of Urology, 2016, 195, .	0.2	0
484	MP21-06 STATE-BY-STATE RACIAL VARIATIONS IN PROSTATE SPECIFIC ANTIGEN SCREENING PATTERNS: A NATIONWIDE ANALYSIS Journal of Urology, 2016, 195, .	0.2	0
485	PD62-12 COMPARATIVE EFFECTIVENESS OF TRIMODAL THERAPY VERSUS RADICAL CYSTECTOMY FOR LOCALIZED MUSCLE-INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER. Journal of Urology, 2017, 197, .	0.2	0
486	Re: Diagnostic Accuracy of Multi-parametric Magnetic Resonance Imaging and Transrectal Ultrasound Biopsy in Prostate Cancer (PROMIS): A Paired Validating Confirmatory Study. European Urology, 2017, 72, 315-316.	0.9	0

#	Article	IF	CITATIONS
487	MP76-05 RADICAL CYSTECTOMY: THE ASSOCIATION BETWEEN DISTANCE TO TREATING FACILITY AND QUALITY OF CARE. Journal of Urology, 2017, 197, .	0.2	0
488	PD72-02 GENOMIC CLASSIFIER AUGMENTS THE ROLE OF PATHOLOGICAL FEATURES IN IDENTIFYING OPTIMAL CANDIDATES FOR ADJUVANT RADIATION THERAPY IN PATIENTS WITH PROSTATE CANCER: DEVELOPMENT AND INTERNAL VALIDATION OF A MULTIVARIABLE PROGNOSTIC MODEL. Journal of Urology, 2017, 197, .	0.2	0
489	PD18-07 THE IMPACT OF TRAVEL DISTANCE TO THE TREATMENT FACILITY ON OVERALL MORTALITY IN PROSTATE CANCER PATIENTS: EVIDENCE FROM THE NATIONAL CANCER DATA BASE. Journal of Urology, 2017, 197, .	0.2	0
490	MP57-18 DEVELOPMENT AND VALIDATION OF NOVEL GENOMIC CLASSIFIERS FOR PREDICTION OF ADVERSE PATHOLOGY AFTER PROSTATECTOMY. Journal of Urology, 2017, 197, .	0.2	0
491	PD43-11 LACK OF SUSTAINABLE RESPONSE TO THE 2012 UNITED STATES PREVENTIVE SERVICES TASK FORCE (USPSTF) RECOMMENDATION AGAINST PROSTATE CANCER (PCA) SCREENING. Journal of Urology, 2017, 197, .	0.2	0
492	PD15-04 A RANDOMIZED CONTROLLED TRIAL EXAMINING THE IMPACT OF THE RETZIUS- SPARING APPROACH ON EARLY URINARY CONTINENCE RECOVERY AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY. Journal of Urology, 2017, 197, .	0.2	0
493	Editorial Comment. Journal of Urology, 2017, 198, 361-361.	0.2	0
494	PD10-10 RACIAL DISPARITIES IN DELIVERING DEFINITIVE THERAPY FOR INTERMEDIATE-HIGH RISK LOCALIZED PROSTATE CANCER: THE IMPACT OF FACILITY FEATURES AND SOCIOECONOMIC CHARACTERISTICS. Journal of Urology, 2017, 197, .	0.2	0
495	MP55-17 ASSESSMENT OF METASTASECTOMY COMPLICATIONS IN RENAL CELL CARCINOMA. Journal of Urology, 2017, 197, .	0.2	0
496	MP04-20 THE ASSOCIATION BETWEEN MORTALITY AND DISTANCE TO TREATMENT FACILITY IN PATIENTS WITH INVASIVE BLADDER CANCER. Journal of Urology, 2017, 197, .	0.2	0
497	MP53-18 EFFICACY OF LOCAL TREATMENT IN PROSTATE CANCER PATIENTS WITH CLINICALLY PELVIC LYMPH NODE-POSITIVE DISEASE AT INITIAL DIAGNOSIS. Journal of Urology, 2017, 197, .	0.2	0
498	PD03-06 CONTEMPORARY TRENDS IN INCIDENCE OF METASTATIC PROSTATE CANCER AMONG US MEN: RESULTS FROM NATIONWIDE ANALYSES. Journal of Urology, 2017, 197, .	0.2	0
499	PD51-05 SURVIVAL ASSOCIATED WITH RADICAL PROSTATECTOMY VERSUS RADIOTHERAPY FOR HIGH-RISK PROSTATE CANCER: A CONTEMPORARY, NATIONWIDE OBSERVATIONAL ANALYSIS. Journal of Urology, 2017, 197, .	0.2	0
500	PD47-08 VARIATION AND TRENDS IN PROSTATE CANCER CARE AT COMMISSION ON CANCER DESIGNATED FACILITIES. Journal of Urology, 2017, 197, .	0.2	0
501	PD67-09 COMPARATIVE EFFECTIVNESS OF ROBOT-ASSISTED VS. OPEN RADICAL CYSTECTOMY. Journal of Urology, 2017, 197, .	0.2	0
502	MP97-04 URINARY CONTINENCE, SEXUAL FUNCTION AND BIOCHEMICAL RECURRENCE 12 MONTHS FOLLOWING ROBOT-ASSISTED RADICAL PROSTATECTOMY: A RANDOMIZED CONTROLLED STUDY COMPARING THE †BOCCIARDI' AND †MENON' TECHNIQUES. Journal of Urology, 2017, 197, .	0.2	0
503	Emergency Department Utilization in Patients With Neurogenic Bladder: Contemporary Burden and National Trends in Prevalence, Inpatient Admission, and Associated Charges, 2006-2011. Urology, 2017, 109, 74-81.	0.5	0
504	Editorial Comment. Journal of Urology, 2017, 198, 1067-1067.	0.2	0

#	Article	IF	CITATIONS
505	Reply. Urology, 2018, 112, 64-65.	0.5	0
506	Re: Stenting prior to Cystectomy is an Independent Risk Factor for Upper Urinary Tract Recurrence. Journal of Urology, 2018, 199, 1069-1070.	0.2	0
507	Reply by the Authors. Urology, 2018, 116, 232-233.	0.5	0
508	Development of the Vattikuti Institute Prostatectomy: Historical Perspective and Technical Nuances. , 2018, , 255-273.		0
509	Functional and Oncological Outcomes of Robotic Radical Prostatectomy. , 2018, , 409-425.		0
510	Robot-Assisted Laparoscopic Radical Prostatectomy in Patients with Clinically High-Risk Prostate Cancer. , 2018, , 363-373.		0
511	Robotâ€assisted radical prostatectomy and a parachute. BJU International, 2018, 121, 820-821.	1.3	0
512	Renal Tumor Size and Presence Of Synchronous Lung Metastasis At Time Of Diagnosis: Implications For Chest Imaging. Urology, 2021, , .	0.5	0
513	Author Reply. Urology, 2021, 153, 361-362.	0.5	0
514	Editorial Comment. Journal of Urology, 2021, , 101097JU000000000000225002.	0.2	0
515	325: Lymph Node Invasion in Prostate Cancer patients with PSA <10 ng/ml: Which Patients Deserve a Pelvic Lymph Node Dissection?. Journal of Urology, 2007, 177, 110-110.	0.2	0
516	329: When to Perform a Bone Scan in Patients with Prostate Cancer. A novel Nomogram. Journal of Urology, 2007, 177, 111-112.	0.2	0
517	1009: Comparison of Holmium Laser, Cold Knife AD Diatermic Incision for the Endoscopic Treatment of Anastomotic Stricture After Radical Retropubic Prostatectomy. Journal of Urology, 2007, 177, 333-333.	0.2	0
518	The importance of pelvic lymph node dissection in the elderly population: implications for interpreting the 2010 national comprehensive cancer network practice guidelines for bladder cancer treatment. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2011, 37, 413-414.	0.7	0
519	A genomic classifier to identify men with adverse pathology post radical prostatectomy who benefit from adjuvant radiation therapy Journal of Clinical Oncology, 2015, 33, 168-168.	0.8	0
520	Prevalence of non-recommended screening for prostate cancer and breast cancer in the United States Journal of Clinical Oncology, 2015, 33, e17528-e17528.	0.8	0
521	Development and validation of an ADT resistance signature to predict adjuvant hormone treatment failure Journal of Clinical Oncology, 2016, 34, 106-106.	0.8	0
522	Efficacy of early and delayed radiation in a prostatectomy cohort adjusted for genomic and clinical risk Journal of Clinical Oncology, 2016, 34, 12-12.	0.8	0

#	Article	IF	CITATIONS
523	Genomic classifier to augment the role of pathological features in identifying optimal candidates for adjuvant radiation therapy in patients with prostate cancer: Development and internal validation of a multivariable prognostic model Journal of Clinical Oncology, 2017, 35, 142-142.	0.8	Ο
524	Is neoadjuvant chemotherapy beneficial before radical cystectomy? Examining the external validity of the SWOG-8710 trial Journal of Clinical Oncology, 2017, 35, 331-331.	0.8	0
525	Testing the impact of adjuvant radiotherapy (aRT) after radical prostatectomy (RP) on overall mortality (OM) in prostate cancer patients with pathologically node positive disease: A nationwide analysis Journal of Clinical Oncology, 2018, 36, 5035-5035.	0.8	0
526	AUTHOR REPLY. Urology, 2021, 158, 115-116.	0.5	0